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Human ISG15 is a 17 kDa ubiquitin-like protein (Ubl) that is induced by type I 
interferons (interferons α and β) and plays a role in antiviral responses. ISG15 is 
conjugated via its C-terminus to more than 150 cellular proteins, and like ubiquitin, an 
E1-E2-E3 enzymatic cascade is required for conjugation. Ube1L and UbcH8 were 
previously identified as the E1 and E2 enzymes for this pathway. My experiments 
identified Herc5, a HECT domain E3, as the major ligase for ISG15. Like ISG15, Ube1L, 
and UbcH8, expression of Herc5 is transcriptionally induced by type I interferons. 
siRNAs against Herc5 abrogated ISG15 conjugation to the vast majority of target 
proteins in interferon-treated cells. Wild type Herc5, but not the catalytically inactive 
C994A mutant, supported conjugation of ISG15 in non-interferon-treated cells co-
 vi 
transfected with Ube1L, UbcH8 and ISG15. IQGAP1, a sc ffold protein, was identified 
as another essential component of the ISG15 system. IQGAP1 was discovered to interact 
with Herc5, and this interaction was mediated by the C-terminal domain of IQGAP1 and 
the N-terminal RCC1-like repeats of Herc5. IQGAP1 was required for auto-conjugation 
of ISG15 to Herc5, and I propose a model where IQGAP1 functions, at least in part, by 
relieving an auto-inhibitory conformation of Herc5.  
Thus, I have identified two factors that are critical for ISG15 conjugation and my 
discoveries have increased our understanding of the ISG15 pathway. Identification and 
characterization of the conjugation apparatus will aid in establishing an i  vitro 
biochemical system for ISG15 conjugation, which in turn, will be important to decipher 
the biological function of ISG15 modification. 
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CHAPTER 1: INTRODUCTION  
1.1 Prelude  
Ubiquitin was first discovered in the bovine thymus in 1974 as an 8.5 kDa 
polypeptide that had lymphocyte differentiating properties (44). It was thought that this 
protein was expressed across all kingdoms of life, including prokaryotes, and hence was 
given the name ubiquitous immunopoeitic polypeptide (UBIP). Later it was discovered 
that a contaminating endotoxin was responsible for stimulating the lymphocytes and that 
this polypeptide was restricted to eukaryotes.  
A few years and several pioneering experiments later, th  role of ubiquitin in 
proteolysis was discovered. It was observed that cell fre  rabbit reticulocyte lysates 
degraded abnormal haemoglobin in an ATP-dependent ma ner (152). This was the first 
time that a cell free proteolytic system that did not i volve lysosomes had been isolated 
(28). Reticulocytes were a useful source to purify and characterize many enzymes 
involved in ubiquitin-proteasome biochemistry (15, 56), probably because of the large 
amount of protein degradation that occurs in reticulo ytes as they differentiate to mature 
red blood cells. Another important milestone in ubiquitin research was the discovery that 
ubiquitin was covalently linked to other proteins, a  first described for histones H2A and 
H2B (43, 73). These discoveries ultimately led to anew paradigm where, in an ATP-




Today we know that ubiquitination is involved in virtually all major cellular 
processes, including the cell cycle and cell division, cell growth and differentiation, the 
activation and silencing of transcription, apoptosis, immune and inflammatory responses, 
signal transduction, receptor-mediated endocytosis and the sorting of proteins in the cell. 
We also know that ubiquitination can take several forms and that it does not always serve 
as a degradation signal. It was due to the huge impact of ubiquitin in many different 
fields of biology that the 2005 Nobel Prize in Chemistry was awarded to Aaron 
Ciechanover, Avram Hershko and Irwin Rose, three sci ntists who played a major role in 
identifying the enzymes and deciphering the biochemistry involved in ubiquitination.  
A major advance in the ubiquitin field was the discovery of ubiquitin-like proteins 
(Ubls), with ISG15 being the first Ubl to be discovered in 1979 (31). Ubls share sequence 
and structural similarity with ubiquitin, and are also conjugated to substrates via their C-
terminal glycine residues. Most Ubls do not target proteins to the proteasome, but have 
various non-proteolytic functions, such as changing the localization, activity or binding 
partners of a substrate (94). The Ubls have greatly contributed to our understanding of the 
Ub/Ubl conjugation machinery. For example, the Nedd8 activating enzyme was the first 
such enzyme to be crystallized and this gave us general insights into the details of 
ubiquitin/Ubl activation (177). 
The main goal of my doctoral research was to understand the mechanism of 
conjugation of ISG15, a ubiquitin-like protein invol ed in the innate immune response. 
When I started the project, the E1 and E2 enzymes for ISG15 had been discovered. I 
identified Herc5, a HECT E3, as the major ligase for this pathway. Further, I showed that 
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the scaffold protein IQGAP1 is an important component of the ISG15 conjugation 
machinery, and that IQGAP1 interacts with Herc5. My findings have enhanced our 
knowledge of the enzymes involved in ISG15 conjugation, which is a prerequisite for 
understanding the biological role of ISG15. 
 
 
1.2 A brief overview of the ubiquitin-proteasome system 
Conjugation of ubiquitin to substrates requires the sequential action of a set of 
three enzymes, the E1, E2 and E3 enzymes (149). The E1 or ubiquitin activating enzyme 
has binding sites for ATP and ubiquitin and it catalyzes the formation of a ubiquitin 
adenylate intermediate which activates the C-terminus of ubiquitin. A high-energy 
thioester bond is then formed between the E1 and ubiquitin by the nucleophilic attack of 
an E1 active-site thiolate on the activated ubiquitn C-terminus, with release of 
pyrophosphate.  E1 also has a binding site for E2 enzymes, and ubiquitin is 
subsequently transferred via a trans-thiolation reaction to the active-site cysteine residue 
of E2 ubiquitin conjugating enzymes. E3 ubiquitin ligases facilitate the transfer of 
ubiquitin from the E2 onto an ε-amino group of a substrate lysine, forming an isopeptide 
bond. Ubiquitin is thus sequentially transferred via the E1-E2-E3 cascade onto the 
substrate. Most organisms have a single E1, a dozen r so E2s and several hundred E3s. 
Consistent with their role in mediating substrate int ractions, E3s are the most abundant 
class of ubiquitinating enzymes.  
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E3s can be broadly classified into two classes: the RING (Really Interesting New 
Gene) type E3s (113) and the HECT (Homology to E6-AP C-terminus) type E3s (70). 
These two classes differ in the manner in which they catalyze substrate ubiquitination. 
The HECT E3s participate directly in the chemistry of ubiquitination, forming a thioester 
intermediate with ubiquitin before it is transferred onto an ε-amino group of a substrate 
lysine. This group of E3s is described in the next section below. RING E3s, on the other 
hand, act as scaffold proteins that bring the E2 in proximity to the substrate, thus 
facilitating the transfer of ubiquitin directly from the E2 to the substrate. The RING 
domain, which typically consists of seven cysteine residues and one histidine residue that 
intercalate a Zn atom, mediates interaction with the E2s (22). The RING E3s occur either 
as single polypeptides (e.g., Cbl, Mdm2) or as multi-protein complexes called Cullin-
RING ligases ( CRLs; e.g., SCF ligases and the APC) (149). SCF ligases are a class of 
well characterized CRLs that are composed of Rbx1/Roc1 (RING-finger protein), Skp1 
(an adaptor protein), Cul1 (scaffold protein) and a F-box protein to mediate substrate 
interaction (147). The globular C-terminus of Cullins interacts with Rbx1/Roc1, which in 
turn binds E2s, whereas the N-terminus recruits subtrates via Skp1 and other adaptor 
proteins. The variable component of SCFs is the F-box protein that binds Skp1 via its F-
box motif and recruits substrates (5). Approximately 70 different F-box proteins have 
been identified in the human genome, and they contain various protein-protein interaction 
motifs such as the WD40 repeats and leucine rich repeats (77). Besides the F-box 
proteins, BTB (broad complex, tramtrack, bric-a-brac) domain proteins, and SOCS/BC 
(suppressor of cytokine signaling/elongin-BC) box proteins can also associate with 
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Cullins to recruit substrates (84, 187). Further, in higher eukaryotes, there are as many as 
seven cullin genes (Cul1-7) which can associate with different adaptor proteins, giving 
rise to hundreds of different SCF-like complexes. Thus, the basic Cullin-Rbx1-adaptor 
architecture is preserved, but owing to the diversity of subunits that can combine to 
assemble this core catalytic complex, the CRLs can target a variety of substrates for 
ubiquitin mediated degradation.  
Another important class of enzymes involved in ubiqit n chemistry is the 
deubiquitinating enzymes (DUBs). It is estimated that t e human genome encodes about 
90 DUBs, regulating various physiological processes (66). A function of DUBs is to 
hydrolyze the isopeptide linkage between the C-terminus of ubiquitin and the substrate 
lysine, thus reversing ubiquitination (4). This also generates free ubiquitin monomers that 
can be recycled before the substrate is degraded by the proteasome. Another important 
biochemical reaction of DUBs is to process ubiquitin precursors into active forms. In 
cells, ubiquitin and most Ubls are produced as a fusion to either ribosomal proteins or to 
other ubiquitin molecules with additional residues extending beyond the last ubiquitin 
monomer (32). These extra amino acids are cleaved by DUBs to generate the 76 amino-
acid active form of the protein with a C-terminal glycine residue.  
Ubiquitin has seven lysine residues (K6, K11, K27, K29, K33, K48 and K63), 
each of which were shown i vivo to form iso-peptide bonds with the C-terminal glycine 
of other ubiquitin molecules (145). The type of linkage used to generate the resulting 
poly-ubiquitin chains determines, to some degree, th  fate of the modified substrate. For 
example, a minimum of four K48-linked ubiquitin molecules are sufficient to direct a 
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substrate to the proteasome (174). K63 chains are involved in cellular processes such as 
DNA repair, receptor endocytosis and NF-κB activation (37, 60, 85). While K63 chains 
can have non-proteolytic functions, there is also evidence that K63 chains can target 
proteins to the proteasome. The biological relevance of other chain types is not yet 
known. Also, it is not clear what determines chain type specificity. In some cases, E2s are 
responsible for the chain type. An example is the E2 heterodimer Ubc13-Mms2, which 
catalyzes K63 chains (121). However, in our lab we observed two distinct chain types 
with the same E2, UbcH7,  functioning with two separate HECT ligases: K48 chains 
with E6AP and K63 chains with Rsp5 (91). Kirkpatrick, et al, used quantitative mass 
spectrometry to show that the anaphase promoting complex (APC), a type of CRL, adds 
multiple mono-ubiquitin molecules on cylin B1, follwing which it catalyzes 
heterogeneous polyubiquitin chains (K63, K11 and K48) (98). More recently, the RING 
E3 Mdm2 was shown to catalyze a heterogeneous polyubiquitin chain that contains all 
seven possible linkages (95).  
K48 linked polyubiquitin chains direct substrates to the 26S proteasome, which is 
a multi-subunit chambered protease. It is made up of a 20S core particle, and a 19S 
regulatory particle also known as the lid. The core particle is a barrel-shaped cylinder 
consisting of a stack of four rings: two identical outer α rings and two identical inner β-
rings (150). Although the α and β rings are made up of similar seven-membered subunits, 
the protease activity resides within the β-ring only. The α-subunits mainly control the 
entry of substrates into and exit of products out of the interior compartments. The main 
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functions ascribed to the regulatory particle are recognition of the K48 chains, gating of 
the proteasome pore, and unfolding proteins before they enter the 20S subunit (150). 
Rpn10/S5A, a subunit of the 19S complex binds polyubiq itin chains and is thought to 
recruit K48-linked substrates to the proteasome (26). However, an Rpn10 deletion in 
yeast causes only a mild defect, indicating that other ubiquitin binding proteins must be 
involved. Opening the orifice at one end of the α-ring, and unfolding substrates are a 
prerequisite to accommodate proteins into this narrow barrel-shaped proteasome. These 
processes require energy, and six different ATPase subunits are found at the base of the 
19S subunit. Rpn11/ POH1 is a Zn2+ dependent metalloprotease that is an essential 
subunit of the 19S complex (3). It removes intact ubiq itin subunits just before the 
unfolded substrate translocates into the pore of the 20S subunit, and this step is essential 
to enhance the rate of proteolysis.  
 
1.3 HECT E3s: 
The defining member of the HECT family of proteins s E6AP (E6-associated 
protein). It was identified as the cellular factor that associated with the E6 protein of 
human papillomaviruses 16 and 18 (HPV16 and HPV18) to target p53 for proteasomal 
degradation (71, 163). High risk HPVs (e.g., HPV16, 8, 33 and 39), are the leading 
cause of cervical cancer because the viral oncogenes, E6 and E7, mediate the degradation 
of p53 and the Retinoblastoma protein (Rb), respectiv ly (65). Besides its role in cervical 
cancer, mutations in UBE3A, the gene encoding E6AP, are the cause of Angelman 
syndrome, a severe neurological disorder (16).     
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Sequence analysis revealed that the C-terminal 350 amino acids of E6AP were 
similar to the C-termini of other proteins, and this domain was named the HECT domain 
(69). HECT proteins have been identified in all eukaryotes and they vary in length from 
90 kDa to over 500 kDa. While the HECT domain mediates catalysis, the N-termini of 
these proteins are involved in substrate recognition. F r example, the yeast HECT E3 
Rsp5, contains three WW domains upstream of the HECT domain, and at least two of 
these mediate interactions with substrates. Also, the E6-binding region of E6AP is a 17 
amino acid peptide, centred approximately 100 residues upstream of the HECT domain. 
The biochemical activities of the HECT domain can be divided into 4 steps: (i) 
interaction with the E2, (ii) trans-thiolation reaction where ubiquitin is transferred from 
the E2 to the HECT active site cysteine, (iii) transfer of ubiquitin onto an ε-amino group 
of a lysine residue on the substrate, (iv) repeat of the activation steps and transfer of 
another molecule of ubiquitin onto one of seven lysine residues of a previously 
conjugated ubiquitin molecule (68). Structural and functional analyses have revealed 
residues important for the first three steps of the reaction. Ongoing research in our lab 
suggests that the C-lobe of the HECT domain (described below) is an important 





























Figure 1.1 The E6AP HECT – UbcH7 complex forms a U-shaped structure. 
The E6AP HECT N-lobe, C-lobe and UbcH7 are in red, green and cyan, 
respectively. The active site loops are in yellow. The dotted line represents 
the distance between the two active site cysteines, which is 40 Å. Reprinted 




The crystal structure of E6-AP HECT domain bound to UbcH7 revealed that the 
HECT domain has a bilobed structure with a short 3-residue hinge connecting the two 
lobes (Fig 1.1) (68). The N-lobe with its mostly α-helical structure has a V-shaped 
hydrophobic groove that pockets a highly conserved Phe residue on the E2. This 
interaction buries a total surface area of 1800 Å, with the Phe side chains making 
extensive van der Waals interactions with E6-AP residues. The C-lobe is smaller and 
bears the catalytic cysteine residue on an active site-loop, which makes contacts with 
both the N-lobe and C-lobe. A highly intriguing aspect of the crystal structure was the 41 
Å distance between the active site cysteine residue of UbcH7 and E6-AP. Trans-
thiolation reaction requires that the cysteine residues of the E2 and E3 are within 2.5 Å of 
each other (176). It was proposed that a major conformational shift might occur to bridge 
the gap between the E2 and the E3 (68). The crystal structure of the HECT domain of 
WWP1, a member of the Nedd4-like family of C2-WW-HECT proteins, showed a similar 
overall bilobed structure (176). However, the two structures differ in the orientation of 
the N-lobe with respect to the C-lobe. While the E6-AP HECT domain resembles an L-
shape, with the C-lobe positioned at one end of the N-lobe, the WWP1 HECT domain 
resembles an inverted T-shape (┴) Fig. 1.2). This difference in orientation resulted in the 
active site cysteine of WWP1 being 16.5 Å apart from the active site cysteine of UbcH5, 
which was modeled into the structure. Further modeling studies on the flexible hinge 
between the N-lobe and C-lobe, reduced this distance to 5 Å. It was suggested that this 
flexible hinge allows the C-lobe, bearing the catalytic cysteine, to move towards the E2 
cysteine residue during each cycle of transthiolatin. The HECT domain of Smurf2, an 
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E3 that targets TGF-β receptors for degradation, was also crystallized (140). The Smurf2 
HECT domain adopted an open conformation, similar to E6-AP, with an even greater 
distance between the active site cysteines (50 Å) of the E2 and E3 (Fig. 1.2). Despite 
these crystal structures, it is still not clear how a HECT domain transfers ubiquitin to 
substrates. Also, a full length HECT E3 has so far not been crystallized, and the 
orientation of the N-terminus with respect to the HECT domain is unknown. It is 
speculated that for each cycle of ubiquitin transfer, the C-lobe receives ubiquitin from an 
E2 at one side of the HECT domain and transfers it to the substrate bound to the N-
terminus on the other side.   
Most HECT domains have a conserved phenylalanine residu  4 amino acids 
before the stop codon (referred to as -4F). This residue was shown to be essential for 
transferring ubiquitin onto a ε-amino group of a substrate lysine by the HECT domain 
(161). Mutating the -4F did not affect thioester bond formation, but it abrogated ubiquitin 
transfer to the substrate. The position of the phenylalanine residue was also important, 
since it was shown that moving it to the -3 or -5 position did not restore function. It was 
proposed that the -4F might be important for correctly orienting the ubiquitin molecule 
while it is tethered by a thioester bond, thus allowing the substrate lysine to access the 




















Figure 1.2 Comparison of the crystal structures of three HECT domains. As compared 
to the E6AP HECT domain, the Smurf2 HECT domain adopts a more open 
conformation, with the distance between the active s te cysteines being 50 Å. The 
WWP1 HECT domain resembles an inverted T (┴), as opposed to an L-shaped 
conformation of the other two HECTs. Reprinted from Ogunjimi et al (140). 
Copyright (2005), with permission from Elsevier. 
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Regulation of HECT E3s 
Relatively few HECT E3s have been characterized with respect to their mode of 
regulation. Some HECT proteins, such as Herc5 and Herc6, are transcriptionally 
regulated (18) (101). Others are regulated by methods such as p o phorylation, 
regulation of E2 recruitment, or recruitment of deubiq itinating enzymes (90). Some of 
these modes of regulation are discussed below. 
Although phosphorylation has been shown to change substrate affinities of HECT 
E3s (19), the study on ITCH was the first to show that phosphorylation can modulate the 
activity of a HECT ligase (38). ITCH is a C2 and WW domain-bearing HECT E3 that 
mediates the ubiquitination and degradation of the transcription factor JunB during T-
helper2 (Th-2) cell differentiation. T-cell activation leads to JNK1-mediated 
phosphorylation of ITCH, which in turn, leads to activation of its catalytic activity (39). 
In the inactive state, the WW domains of ITCH bind to the HECT domain of this protein. 
This intramolecular inhibition is relieved when JNK1 phosphorylates ITCH at three sites 
within a proline rich region (PRR). Phosphorylation of ITCH causes a conformational 
change in the E3 that allows it to access its substrate JunB (38). 
TGF-β signaling plays a role in many cellular processes involving growth and 
differentiation (156). This pathway is regulated at multiple steps, including ubiquitination 
and degradation of the TGF-β receptors by Smurf 1 and Smurf2, which terminates th  
signal. Smurf proteins, which belong to the C2-WW-HECT family of proteins, are 
recruited to the TGF-β receptors via their interaction with the adaptor protein SMAD7 
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(86). SMAD7 helps not only to localize the Smurfs but also to activate them. It was 
shown that the N-terminus of SMAD7 facilitates the interaction between the Smurf 
HECT domain and the cognate E2, UbcH7 (140). The crystal structure of Smurf2 
revealed that it has a sub-optimal E2-binding pocket, with hydrophilic residues instead of 
the more typical hydrophobic residues seen in other HECT domains. SMAD7 overcomes 
this structural impediment by facilitating an interaction between the E2 and the HECT 
domain, thus increasing the activity of Smurf2. 
The deubiquitinating enzymes (DUBs) USP8 and USP15 are associated with the 
RING E3s Nrdp1 and Rbx1, respectively (57, 185). They were shown to reverse the auto-
ubiquitination of these ligases, thereby rescuing them from proteasomal degradation. The 
only HECT E3 that is known to interact with a DUB is Rsp5, an essential E3 in 
Saccharomyces cerevisiae. Rsp5 associates with Ubp2, a DUB, and the interaction is 
mediated by an adaptor protein Rup1 (91). Rsp5 preferentially adds K63 chains of 
ubiquitin onto substrates in vivo and in vitro (92). Ubp2 was shown to reverse K63-
specific ubiquitin conjugation on Rsp5 substrates in vitro. Genetic evidence also indicates 
that Ubp2 antagonizes the function of Rsp5 in vivo. Physical association of a 
deubiquitinating enzyme with an E3 is a novel mechanism to regulate the activity of an 
E3. 
HECT proteins and viruses 
HECT E3s play important roles in several physiological processes and some of 
them are involved in fighting viral infections, whereas others are hijacked by viral 
proteins and aid viral replication. APOBEC3G is an antiviral molecule with cytidine 
 
15 
deaminase activity. It is packaged into retroviral p rticles as HIV-1 buds from the cells. 
The deaminase activity induces G-A mutations in the viral genome, many of which are 
lethal to the provirus (194). Nedd4-1, a HECT E3, ubiq itinates APOBEC3G and this 
serves as a signal to target the antiviral protein to the cell membrane, where it interacts 
with Gag and is subsequently packaged into the virus particles (24). The virus has 
evolved to counter this defense mechanism of the host. The Vif protein of HIV-1 
interacts with cellular proteins to form a Vif-Cul5-SCF-like ligase that induces 
ubiquitination and degradation of the antiviral factor APOBEC3G (191). As part of my 
research, I discovered that a HECT E3 Herc5, is the major ligase for an antiviral 
ubiquitin-like protein, ISG15 and the results are described in Chapter 3 (18). 
One of the best studied examples of viruses taking co trol of cellular machinery is 
that of the HPV protein E6, which alters the target specificity of the cellular HECT E3 
E6-AP. High risk HPVs (e. g., HPV16, 18, 33 and 39)are associated with 95% of human 
cervical carcinomas, while the low risk HPVs are associated only with benign tumors 
(201). E6 can simultaneously associate with both E6-AP and p53, hijacking the ligase 
activity of E6AP and directing it towards p53 (71). As a result, p53 is ubiquitinated and 
targeted for proteasomal degradation.  
The Epstein-Barr virus (EBV) latent membrane protein (LMP) 2A, plays a role in 
maintenance of viral latency by blocking B-cell signaling. The phosphorylation of 
LMP2A on its cytoplasmic domain recruits tyrosine kinases Syk and Lyn, via their SH2 
domains (33). Further, the N-terminal region of LMP2A has PPPY motifs which interact 
with the WW domains of AIP4 and Nedd4-2. These ligases mediate the ubiquitination of 
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LMP2A-associated kinases Syk and Lyn, resulting in their down-regulation (183). Thus 
the viral protein acts as a scaffold to recruit HECT E3s and their substrates and disrupts 
B-cell receptor (BCR) signaling. 
Many enveloped viruses exploit the activity of HECT E3s to stimulate 
ubiquitination of Gag proteins, an essential step for budding of viruses. A recent study 
reported that HECT domain proteins like WWP1 and WWP2 are recruited by viral 
proteins with PPXY motifs, to promote the budding of murine leukemia viruses (MLV) 
(118). Also, it was shown that Nedd4-1 catalytic activity was critical for the budding of 
human T-cell leukemia virus type 1 (HTLV-1). The HTLV-1 Gag protein contains a 
PPxY sequence which interacts with the WW domains of the HECT ligase Nedd4-1 and 
recruits it to the plasma membrane. Subsequently, Nedd4-1 ubiquitinates the Gag protein, 




1.4 Ubiquitin-like proteins 
A number of proteins have been identified that structurally resemble the three-
dimensional β-grasp fold of ubiquitin. They are of two types: the ubiquitin domain 
proteins (UDPs) and the Ubiquitin-like proteins (Ubls) (178). UDPs have a ubiquitin-like 
domain in the context of a larger protein but they do not have a C-terminal glycine that 
can be conjugated to other proteins. The S. cerevisiae protein Rad23 is the best 
characterized example of this class. It has a ubiquitin-like domain at its N-terminus and 
two ubiquitin associated domains (UBA) in the latter part of the protein. The ubiquitin-
like domain of Rad23 binds the Rpn1 subunit of the proteasome, whereas the UBA 
domains interact with polyubiquitinated proteins (14, 26). In this manner, Rad23 
functions as an adaptor to recruit polyubiquitinated substrates to the proteasome. The 
other type of proteins that structurally resemble ubiq itin are the Ubls. Like ubiquitin, 
they are expressed as C-terminal extensions, which are processed to generate a C-
terminal glycine residue. This glycine residue can form isopeptide linkages with lysine 
side chains on substrates (94). Each Ubl also has a distinct set of E1-E2-E3 enzymes, 
although in some cases, overlap with the ubiquitin enzymes has been observed (186, 
196). Ubls and their enzymes have contributed to our understanding of the ubiquitin 
conjugation machinery. Crystal structures of Ubl enzymes have given us insights into the 
mechanisms of ubiquitin enzymes (177). About 10 Ubls have been discovered so far (55) 




SUMO: Small Ubiquitin-related Modifier 
SUMO shares ~18% identity with ubiquitin, yet its core structure is nearly 
identical to that of ubiquitin (8). There is a single essential SUMO gene in 
Saccharomyces cerevisiae (SMT3) but the human genome has three genes (SUMO 1-3). 
Like other Ubls, the first step in SUMO conjugation is catalyzed by an activating 
enzyme, which in this case is a heterodimer of Sae1 and Sae2 (81). Sae1 and Sae2 
correspond in sequence to the N-terminus and C-terminus of Ube1, the E1 for ubiquitin. 
Ubc9 is the only known SUMO E2 enzyme (79). Ubc9 is distinct from other E2 enzymes 
in that it mediates substrate interaction. Most substrates are sumoylated on a conserved 
ΨKXD/E motif (where Ψ is a bulky aliphatic group and X is any amino acid), which is 
recognized by Ubc9 (9). Not all proteins that bear this motif are sumoylated, indicating 
that the structural context of this sequence is also important. Although in vitro E1 and 
Ubc9 are sufficient to transfer SUMO onto most substrates, efficient SUMO conjugation 
requires ligases or E3s (80). Also, in S. cerevisiae, almost all SUMO conjugation is 
dependent on E3s. SUMO E3s, like the RING E3s of the ubiquitin pathway, do not form 
covalent intermediates with the Ubl, but function by bringing the E2 in proximity to the 
substrate. Three classes of E3s have been recognized for the SUMO pathway. The first 
belongs to the Protein Inhibitor of STAT (PIAS) family of proteins, which bear an 
unusual RING-like motif. These proteins bind directly to Ubc9 and the substrates to 
stimulate SUMO conjugation. The second ligase is the vertebrate-specific protein 
RanBP2, which is a component of the nuclear pore complex (148). The 30 kDa catalytic 
core of RanBP2 contains neither RING domains nor HECT domains. It is not clear 
 
19 
whether RanBP2 is required in vivo for the sumoylation of proteins other than RanGAP1. 
The third type of SUMO ligase is Pc2, a member of the polycomb group of proteins (83). 
Polycomb proteins are involved in DNA methylation and epigenetic silencing of 
chromatin. CtBP, a transcriptional corepressor is recruited to the polycomb complex via 
Pc2 and Pc2 promotes sumoylation of CtBP both in vivo and in vitro.  
Sumoylation plays a role in many diverse cellular pthways. At the molecular 
level, SUMO modification masks or adds a protein-protein interaction surface, thus 
altering function. SUMO modifications on transcription factors, in most cases, lead to 
transcription repression. In fact, translational fusions of SUMO to DNA binding proteins 
are sufficient to reduce promoter activity, suggesting hat SUMO recruits repressors (78). 
Sumoylation is also involved in DNA repair via modification of the base excision repair 
enzyme, thymine DNA glycosylase (TDG). It was demonstrated in vitro that sumoylated 
TDG is capable of multiple rounds of catalysis as opposed to the unmodified enzyme. It 
is thought that SUMO modification reduces the affinity of the enzyme for its product, the 
AP site, and results in an increase in enzyme turnover (52).  
In some cases, SUMO competes with ubiquitin to modify substrates, antagonizing 
the effect of ubiquitin conjugation. Lys 164 on proliferating cell nuclear antigen (PCNA) 
can be modified by ubiquitin as well as SUMO, resulting in different outcomes. 
Ubiquitination at this site is required to repair DNA lesions whereas SUMO modification 
at this site inhibits the damage-induced DNA repair thway (51). In a similar manner, 
IκBα was reported to be sumoylated on the same lysine residue to which ubiquitin is 
conjugated. Ubiquitination of IκBα leads to its degradation, thus activating NFκB and the 
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inflammatory response pathway. Sumoylation, on the ot r hand, was proposed to block 
IκB degradation, and inhibit NFκB-mediated transcription (23).  
RanGAP1 is the GTPase activating protein for the small GTPase Ran, which is 
involved in nuclear trafficking. RanGAP1 is the most abundant SUMO modified protein 
in vertebrate cells. The function of SUMO-RanGAP1 in nuclear transport is not yet clear, 
but in vitro nuclear import assays show that it is critical for the sumoylated form of the 
protein to be tightly associated at the nuclear pore c mplex (NPC). The SUMO E3, 
RanBP2 is localized on the cytoplasmic side of the NPC and the SUMO peptidase 
SENP2 is on its nuclear side. This has given rise to a model wherein proteins are rapidly 
sumoylated and desumoylated as they are shuttled into the nucleus (115, 120).  
 
NEDD8/Rub1  
NEDD8 shares the highest sequence identity with ubiquitin (~60%). Like SUMO, 
the E1 for NEDD8 is a heterodimer composed of two proteins, APPBP1 and UBA3 (45). 
The NEDD8 activating enzyme was the first E1 to be crystallized and its structure 
provided many insights into the mechanisms of ubiquitin/Ubl activation, E1-E2 
interactions, and transfer of ubiquitin/Ubl from E1to E2 (67, 177) . The crystal structure 
revealed that amino acid 72 of the Ubl is an important determinant for E1 specificity for 
this pair. Ubiquitin has an arginine at this position whereas NEDD8 has an alanine. A 
single amino acid substitution A72R, allows NEDD8 to form an efficient thioester bond 
with Ube1, while hampering thioester bond formation with its cognate E1 (177). Ubc12 
was initially identified as the NEDD8 conjugating enzyme based on the observation that 
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deletion of Ubc12 and no other E2 abrogated NEDD8 conjugation in yeast. Roc1/Rbx1 
and Mdm2 are suggested to be E3s for this pathway (128, 186). Both Roc1 and Mdm2 
are RING domain proteins, but while Mdm2 is a single polypeptide with E3 activity, 
Roc1 is a component of the cullin-based E3s.  
Until recently, the only known substrates for NEDD8 conjugation were the 
Cullins, which are the scaffolding proteins for theCullin-RING ligases (CRLs). NEDD8 
is ligated to a single conserved lysine residue on cullins, which activates the SCF ligase 
because it prevents the binding of CAND1 (cullin-associated and neddylation-
dissociated-1), an inhibitor of SCFs (110). NEDD8 conjugation also boosts SCF activity 
by recruiting the ubiquitin conjugating enzyme to the cullin (89). It was also shown that 
neddylation of cullins makes them unstable and the activity of COP9 signalosome (CSN) 
is required to recycle them to the unneddylated, stable forms (184).  
In 2004, Xirodimas et al showed that Mdm2, a RING finger ubiquitin ligase, 
promotes NEDD8 conjugation to the tumor suppressor p53 (186). It was deduced that 
neddylation inhibits the transcription activation function of p53, since p53 mutants that 
cannot be conjugated to NEDD8 display increased transcriptional activity compared to 
wild type p53. Mdm2 is itself auto-conjugated to NEDD8, but this does not affect its 
ability to ubiquitinate p53. 
NUB1 (NEDD8 ultimate buster 1) was identified as a negative regulator of 
NEDD8 conjugation. NUB1 is a ubiquitin like protein that interacts with Rpn10/S5a 
subunit of the 19S proteasome subunit. NUB1 is thoug t to act as an adaptor to recruit 
neddylated proteins to the proteasome for degradation (171). It was also shown that 
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NEDD8 conjugated as the fourth subunit onto a K48 linked ubiquitin trimer, can directly 
bind to the 26S subunit of the proteasome (181). This result suggests that NEDD8 has all 
of the determinants necessary for targeting to the 26 S proteasome in the context of a 
Lys-48-linked chain. 
Not surprisingly, the NEDD8 pathway is essential for cell cycle progression, since 
many SCF targets are regulators of cell cycle. In fission yeast, disruption of NEDD8 
conjugation is lethal, and Uba3-/- mice are not viable (173). The mutant mice embryos 
showed aberrant expression of p27Kip1, CyclinE and β-catenin, all substrates of the SCF 
ubiquitin ligases. Further, accumulation of NEDD8 has been observed in a number of 





Interferon-Stimulated Gene 15 
ISG15 is one of the genes to be induced early in response to interferons α and β 
(31). It encodes a 17 kDa protein with two ubiquitin-like domains (48) and was shown to 
have anti-viral function (106). The biochemical functions of ISG15 modification are not 
known, although it was the first Ubl to be discovered. Some of the reasons for the slow 
progress in our understanding of this Ubl are that ISG15 is found only in vertebrates, 
making genetic approaches difficult. Also, until recently, the enzymes involved in ISG15 
conjugation and the substrates that are modified by ISG15 were not known.  
The crystal structure of ISG15 (Fig. 1.3), determined at 2.4 Å resolution, shows 
two ubiquitin-like domains with a six residue linker connecting them (135). Both 
domains of ISG15 maintain the β-grasp fold that is typical of the ubiquitin structre. The 
two ubiquitin-like domains bury 627 Å surface area between them, corresponding to 7% 
of the total solvent accessible surface of the protein. The contact surface between the two 
domains involves mainly van-der-Waals interactions a d a weak hydrogen bond. 
Although this is thought to be the most stable soluti n structure, the authors concede that 
it is possible for the relative orientation of the two domains to change when ISG15 
























 Figure 1.3 Structure of ISG15 resembles that of ubiq itin. A)  A ribbon diagram of 
ISG15, showing the two ubiquitin-like domains connected by a flexible linker. B) An 
overlay of the ribbon diagrams of ubiquitin (pink) and the N- terminal (blue) and C-
termainal (green) domains of ISG15. All three structures show the characteristic β-grasp 





As with ubiquitin, a set of three types of enzymes, acting in sequential order, are 
responsible for the conjugation of ISG15 to its substrates. The Krug lab identified Ube1L, 
an enzyme highly homologous to the E1 of ubiquitin, as the E1 for ISG15 (193). 
Biochemical studies identified UbcH8 as the E2 for ISG15, a result that was confirmed 
by siRNA experiments (196). UbcH8 has been reported to be an E2 for ubiquitin as well 
(102, 130, 175, 195), suggesting possible cross-talk between the ubiquitin and ISG15 
pathways. However, biochemical studies in our lab suggest that UbcH8 is not an efficient 
E2 for the ubiquitin system. The Km value of Ube1L for UbcH7 was estimated to be at 
least 50 times higher than for UbcH8, while the Km for UbcH8 was comparable to the 
values for other known E1-E2 pairs (Durfee L and J.M.H. - submitted to J Biol Chem). 
Both Ube1L and UbcH8 enzymes, like ISG15, are induce  at the transcriptional level by-
IFN-β. A major focus of my work has been to identify theligase for ISG15. Herc5, a 
HECT E3, was determined to be a major ligase for this pathway and these results are 
described in Chapter 3.   
Ubp43 (Usp18 in humans) was identified as the protease that cleaves ISG15 from 
ISG15 conjugated substrates. Although Ubp43 has several key residues that are 
conserved in ubiquitin-specific proteases (USPs), and it was shown to cleave Ub-β-gal 
fusions in Escherichia coli (111), it was later reported to be an ISG15 specific protease 
(117). Ubp43-/- mice are hypersensitive to type I interferons and exhibit neurological 
defects. Initially, the cause of these physiological defects was attributed to the 
accumulation of ISG15 conjugates in the brain. However, a double knockout mouse 
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lacking both Ubp43 and ISG15 genes still showed the same abnormalities and it was 
therefore concluded that the Ubp43-/- phenotype was not related to ISG15 (100). Also, 
since the Ubp43-/- mice showed ISG15 conjugates, it i  clear that Ubp43 is not 
responsible for processing the inactive ISG15 precursor. When the C-termius of ISG15 
was derivatized with a Vinyl-sulfone residue (ISG15-VS), it reacted with USP5, a 
previously known deubiquitinating enzyme, but not with Ubp43 (54). This method of 
tagging Ubls with VS is used to identify enzymes that react with a given Ubl. Given the 
above information, it is not clear whether Ubp43 is an actual ISG15 deconjugating 
enzyme, and if so, whether it is the only ISG15 deconjugating enzyme. 
A large scale proteomics experiment identified the targets of ISG15 conjugation 
in IFN-β-treated HeLa cells using affinity purification foll wed by mass-spectrometry 
(197). The substrates identified included interferon-induced as well as constitutively 
expressed proteins, functioning in a range of cellular activities. There were a sizeable 
number of proteins involved in RNA processing and chromatin remodeling, suggesting 
that ISG15 might play a role in regulating transcription and/or RNA splicing events 
during microbial infections. It was not surprising that Ube1L, UbcH8 and Herc5 were 
among the substrates identified, since enzymes involved in the conjugation of Ub/Ubls, 
are often auto-conjugated (21, 145). Further, JAK1 and STAT1, the proteins involved in 
signal transduction from the interferon receptors, were also modified.  
The consequences of ISG15 modification are not clear, but it appears that targets 
are not directed to the proteasome (116) and in fact, some substrates have been reported 
to be stabilized by ISG15 conjugation. An example is the transcription factor IRF3, 
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whose activity is tightly controlled by ubiquitin mediated degradation (114). In 
interferon-treated cells, IRF3 was shown to be conjugated to ISG15. This resulted in 
increased stability of the protein, which led to elevated levels of transcription activation. 
There have also been isolated reports of ISG15 modified proteins showing a decrease or 
increase in activity. The protein phosphatase 2Cbeta (PP2Cbeta), which is involved in 
NFκB pathway, was shown to have a decreased activity when it was conjugated to ISG15 
(169). 4EHP, an mRNA cap-binding protein and a suppressor of translation, was reported 
to be modified by ISG15 via the RING-type ligase HHARI and this increased its cap-
binding affinity (142) . However, the data suggested that the increase in cap-binding 
affinity was not significant.    
As with SUMO, it has been observed that ISG15 is conjugated to only a small 
percentage of the total pool of a given subsrate. It is difficult to explain how ISG15 can 
modulate the function of a substrate if only a small fr ction of the substrate is modified. 
SUMO is similarly conjugated to a low percentage of m st substrates. A model has been 
proposed to explain SUMO conjugation (52, 78), which might also hold true for ISG15. 
In the case of thymine DNA glycosylase (TDG), SUMO conjugation is required to 
decrease its affinity for its product, an abasic site, thus allowing multiple rounds of 
catalysis. Once it is dissociated from the AP site, TDG is deconjugated to prepare it for 
the next round of reaction. In this way, even though very little TDG is modified at any 
given time, the whole population is affected by sumoylation. This model can be applied 
to other proteins. For example, a protein might need to be conjugated to become part of a 
protein complex, but the conjugation status of the protein may not be important once it is 
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within the complex. Thus it was proposed that a cycle of conjugation and deconjugation 
might be occurring such that conjugation is required to change the status of a protein, but 
not to maintain it. At any given time, even though two molecules of a substrate may be 
unconjugated, their functions might be different based on their conjugation histories.  
ISG15 as an anti-viral molecule 
It has long been suggested that ISG15 plays an antiviral role since it is one of the 
proteins that is turned on early during interferon esponses. This was supported by the 
fact that the NS1 protein of influenza B virus binds ISG15 and blocks its conjugation to 
cellular proteins (193). The NS1B protein was shown to inhibit the ISG15~Ube1L 
thioester bond in vitro, preventing Ubl activation.  
The most convincing demonstration of ISG15 antiviral activity came from 
experiments by H.W. Virgin’s group. ISG15 expressed in mice lacking the interferon α/β 
receptor (IFNAR-/-) was shown to rescue Sindbis virus lethality (105). Further, the last 
six amino acids, LRLRGG, were shown to be important for mediating protection against 
the infection, stressing the importance of conjugation of ISG15 to targets. In another 
paper, the same group also demonstrated that ISG15-/- mice were more susceptible to 
infections of influenza A virus, influenza B virus, herpes simplex virus type 1 and 
Sindbis virus (106). The increased susceptibility of these mice to Sindbis virus infection 
was rescued by expressing wild-type ISG15, but not he non-conjugatable form. Another 
report showed that ISG15 could produce the same effects as interferon treatment, that is, 
inhibit the budding of virions in HIV-1 infected cells (141). Knock-down of ISG15 by 
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siRNA treatment rescued virus replication in interferon-treated cells. These experiments 
clearly established ISG15 as an antiviral molecule against both RNA and DNA viruses. 
Viruses have evolved ways to block ISG15 conjugation, an example of which is 
the NS1B protein mentioned above. Recently it was shown that OTU domains, first 
discovered in the ovarian tumor protein, have deISGylating activity. OTU domain 
proteins are a class of cysteine proteases, some of which display de-ubiquitinating 
activity. A classic example is that of the protein A20 which plays a role in down 
regulation of NF-kappaB activity by deubiquitinating K63 linked chains on the substrate 
RIP. Giannakopoulos et al have shown that OTU domains from Nairoviruses and 
Arteriviruses have the ability to de-conjugate ubiqitin as well as ISG15. Co-transfection 
of OTU domains into 293T cells along with the ISG15 conjugation machinery, led to a 
decrease in ISG15 conjugates. Further, co-expression of OTU domains along with ISG15 
abolished the ISG15-mediated viral resistance in IFNAR-/- mice. Thus, viruses have 
evolved such that their OTU domains can de-conjugate ISG15 as a means to evade the 
host immune response. 
 
1.5 Innate Immune response 
Innate immunity is the non-specific or generalized r sponse of the body to the 
presence of pathogens such as virus or bacteria. It is the first line of defense against these 
micro-organisms and is responsible for their early detection and elimination, giving the 
body enough time to prime its adaptive immune system. It involves (i) the  recognition 
of pathogen-associated molecular patterns by a set of molecules called pattern 
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recognition molecules (PRRs) (ii) the initiation of a downstream cascade of signals that 
result in the transcription of pro-inflammatory cytokines and type I interferons  (164). 
The type I interferons, such as IFN-α and IFN-β, have anti-viral and anti proliferative 
functions and play a central role in mounting the innate immune response (62).  
 
Toll-like receptors and downstream signaling 
In order to have an effective response, the immune system needs to efficiently 
detect the invading micro-organisms. One major class of PRRs are the toll-like receptors 
(TLRs) that are encoded by cells of the innate immune system such as dendritic cells. 
First discovered in Drosophila where they mediate anti-fungal innate immunity, TLRs are 
the principal receptors that recognize molecular motifs associated with bacteria, fungi and 
viruses. There are 11 members in the TLR family, TLR1-11, recognizing diverse 
microbial signature molecules such as lipopolysacchrides (LPS), flagellin, dsRNA, 
ssRNA and unmethylated CpG DNA (1). They may be located on the cell surface where 
they mainly recognize bacterial components such as LPS, or within endosomes where 
they target viral DNA products. 
All TLRs have an extracellular leucine-rich repeat domain (LRR), a single 
transmembrane domain and a Toll-Interleukin1 receptor (TIR) domain. The LRR 
mediates recognition of the pathogen-associated molecular patterns, with each TLR 
recognizing a specific microbial molecule (2). For example, TLR3 recognizes viral 
dsDNA while TLR5 is specific for flagellin. The TIR domain recruits downstream 
adaptors to transduce signals, which culminate in the activation of NF-κB and other 
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transcription factors. Signaling from all TLRs except TLR3 involves the Myeloma 
Differentiation factor (MyD88), a TIR domain containing adaptor protein that recruits 
downstream kinases IRAK1 and IRAK4 and the RING-type ubiquitin ligase TRAF6. 
TRAF6, along with the ubiquitin conjugating enzymes Ubc13-Uev1A, forms K63-linked 
ubiquitin chains which activate the kinase complex consisting of TAK1, TAB1 and 
TAB2 (20, 179). TAK1 activates IκB Kinase (IKK), resulting in the activation of NF-κB. 
The IL-1 receptor associated kinases (IRAKs) can activ te IRF7, which leads to the 
induction of type I interferons. TLR3 is the only receptor that uses a MyD88-independent 
pathway that involves TLR-associated activator of interferon (TRIF) and the IKK-like 
kinases – TBK1 and IKKε, which activate transcription factors IRF3 and IRF7 (189).  
All TLRs activate a set of signaling molecules that result in the activation of 
transcription factors NF-κB and AP-1 (a heterodimer of activating transcription factor 2 
with c-JUN). These lead to expression of genes requi d for inflammatory and adaptive 
immune responses, such as IL-6, and tumor necrosis factor (TNF). Additionally, TLRs 
3,4,7,8 and 9 also activate interferon regulatory factor-3 (IRF3) and/or IRF7 (87). The 
latent IRFs are cytosolic and upon phosphorylation, they dimerize and translocate to the 
nucleus. All these transcription factors (NF-κB, AP-1, IRF3 and/or IRF7) along with the 
high mobility group protein1 (HMG-1) assemble into a complex called the 
enhanceosome (97) which binds to the promoter of IFN-β gene and initiates transcription. 
IFN-β is secreted out of the cell and acts in a paracrine and autocrine manner to initiate a 
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cascade of events that lead to the expression of hundreds of ISGs, which in turn induce an 
anti-viral state in the host.  
A type of pattern recognition receptors that are different from the TLRs are the 
retinoic acid inducible gene I (RIG-I) like helicases. These proteins have a DExD/H box 
class of helicase domain that recognizes viral dsRNA (190). The N-terminus has two 
caspase recruitment domains (CARDs) that mediate downstream signaling. Binding of 
viral dsRNA induces a conformational change that allows the RIG-I CARDs to form 
homotypic interactions with CARDs from a mitochondrial anti-viral signaling protein 
(MAVS, also called IPS-1/VISA/ CARDIF) (88, 124, 165, 188). MAVS activates the 
kinases responsible for activation of IRF3 and NF-κB, which in turn leads to production 
of IFN-β.  
 
Type I interferons  
Historically, interferons were molecules that were able to ‘interfere’ with viral 
replication and establish an anti-viral state. Type I interferons include IFN-α, IFN-β and 
seven other classes of IFNs (146). There is a single gene for IFN-β, whereas there are 20 
genes that encode 13 subtypes of IFN-α. The IFN-α genes are clustered on one 
chromosome and are thought to be a product of gene duplication. The various sub-types 
have minor amino-acid differences, but differ in their expression profiles and the subset 
of genes they activate. Almost all cell types produce IFN α and β, but plasmocytoid 
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dendritic cells (pDCs) or ‘natural IFN-producing cells’ secrete the highest amounts of 
type I interferons (168).  
There is a common receptor for IFNs α and β that is ubiquitously expressed on 
cell surfaces. It is composed of two subunits - IFNAR1 and IFNAR2 (138). IFN-β 
binding causes the two subunits to dimerize and begin a signal transduction cascade that 
culminates in the induction of several hundred Interferon Stimulated Genes (ISGs). Tyk2 
and JAK1 are two members of the Janus tyrosine kinases that are associated with 
IFNAR1 and IFNAR2 respectively. Dimerization of the receptor leads to Tyk2 
phosphorylation, which in turn phosphorylates JAK1. The two activated kinases 
phosphorylate the IFNAR1 subunit of the receptor, t create a docking site for Signal 
Transducer and Activator of Transcription-2 (STAT-2). STAT2 binds phosphorylated 
IFNAR1 via its SH2 domain, and recruits STAT1 (107). The two proteins form a 
heterodimeric complex that dissociates from the recptor and moves to the nucleus. 
Within the nucleus, the STAT1-STAT2 heterodimer associates with IRF9/p48 to form a 
transcription complex ISGF3 (interferon-stimulated gene factor 3). This multisubunit 
complex activates IFN-α and other genes with the interferon stimulated respon e element 
(ISRE) in their promoters (166). Knockout mice reveal the importance of the IFN α/β 
receptor in establishing the host response to viruses. These mice are extremely sensitive 
to infections by Poxviridae, Arenaviridae, Rhabdoviridae and  Togaviridae family of 

















Figure 1.4 Type I IFN induction, signaling and action. Left panel: dsRNA, a 
characteristic by-product of virus replication, leads to activation of the transcription 
factors NF-κB, IRF-3 and AP-1 (not shown). The cooperative action of these factors is 
required for full activation of the IFN-β promoter. IRF-3 is phosphorylated by the 
kinases IKK( and TBK-1 which in turn are activated by the RNA-sensing complex of 
RIG-I, MDA5 and IPS-1/MAVS. A second signaling pathway involves endosomal TLR-
3 and TRIF. Right panel: Newly synthesized IFN-h binds to the type I IFN receptor 
(IFNAR) and activates the expression of numerous ISGs via the JAK/STAT pathway. 
IRF-7 amplifies the IFN response by inducing the expr ssion of several IFN-h subtypes. 
SOCS and PIAS are negative regulators of the JAKSTAT pathway. Mx, ISG20, OAS 
and PKR are examples of proteins with antiviral activity. Adapted from Haller et al (50). 




Interferon regulatory factors (IRFs) 
IRFs are the transcription factors responsible for m dulating the expression of 
interferons and interferon stimulated genes (ISGs). There are nine IRFs encoded in the 
human genome, with IRF1 being the first family membr to be discovered (61). Of these, 
IRF3 and IRF7 are involved in the early response to microbial infections. IRF9 
complexes with STAT1-STAT2 to form the complex known as ISGF3 that initiates 
transcription of IFN stimulated genes. Some, such as IRF2 and IRF4, act as repressors of 
interferon responsive genes. Other IRFs regulate the xtent of induction of IFNs and pro-
inflammatory cytokines.  
All IRFs have a conserved N-terminal DNA binding domain that forms a helix 
turn helix. Crystal structure of IRF2 bound to DNA revealed that 5’AANNGAAA-3’ is 
the consensus sequence recognized by all IRFs (151). The C-terminal regulatory region 
of all IRFs (except IRF1 and IRF2) consists of an IRF association domain (IAD), through 
which these proteins interact with each other as well as other transcription factors like 
STAT proteins. The crystal structure of the IAD of IRF3 revealed that the H1 and H5 
helices form a condensed inactive structure, which could be a possible auto-inhibition 
mechanism (151). Phosphorylation at multiple sites relieves this interaction, allowing the 
IRFs to bind DNA and other transcription factors. Besides phosphorylation, other post-
translational modifications are also used to regulate the activities of some IRFs. 
Acetylation of IRFs1, 2 and 7 was shown to modulate their activities, with IRF2 being 
acetylated in a cell cycle dependent manner (144). Activation of IRF7 involves K63 
ubiquitination via TNF-receptor associated factor 6 (TRAF6), a ubiquitin ligase (144). 
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Some viruses are known to down-regulate IRFs as a means to circumvent the 
interferon response. The RTA factor of Kaposi’s Sarcoma-Associated Herpesvirus 
(KSHV) and the NSP1 of Rota virus were shown to induce poly-ubiquitination and 
degradation of IRF7 and IRF3 respectively (6, 192). On the other hand, certain viruses 
take advantage of the transcription activation functio  of IRFs. IRF1 was shown to bind 
to an ISRE-like element in the genome of human immuno-deficiency virus-1 (HIV-1), 
which led to stimulation of transcription from the viral LTR (7). 
 
Interferon Stimulated Genes (ISGs) 
As part of the innate immune response, ISGF3, a complex of STAT1-STAT2 and 
IRF9, binds consensus DNA elements upstream of IFN α/β inducible genes. There are 
more than 300 interferon stimulated genes (ISGs), which mediate the antiviral effects of 
interferons (168). Some of these and their mechanisms of interference with the viral 
machinery have been described below: 
 
PKR: dsRNA dependent protein kinase 
PKR is one of the better-studied interferon-induced proteins that plays an 
important role in fighting viral infections (123). The N-terminal domain of PKR binds 
dsRNA, whereas the C-terminus has a kinase domain. Although some PKR is 
constitutively present in a cell, it is in an inactive form. Binding of dsRNA causes 
dimerization, auto-phosphorylation and activation of the kinase domains (36). The 
activated PKR phosphorylates the α-subunit of translation initiation factor 2 (eIF2α, 
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which blocks the eIF2B-mediated GTP exchange reaction. This renders eIF2 inactive and 
inhibits translation of most viral and cellular mRNAs (40). Many viruses have devised 
ways to block PKR function. One example is that of the NS1 protein of influenza A virus, 
which binds PKR and inhibits its activity (125).  
 
2’-5’OAS-RNaseL system 
The 2’-5’OAS-RNaseL system is another well-characterized pathway that is 
turned on by interferons to counter viral infections (82). 2’-5’ oligo-adenylate synthetases 
(2’-5’OAS) are a small family of proteins that are induced by interferons and activated by 
dsRNA, a common by-product of viral infection. Upon bi ding dsRNA, these enzymes 
convert ATP molecules into unique 2’-5’ phospho-diester-linked adenylate oligomers 
(abbreviated as 2-5A). RNAseL, an endoribonuclease that is constitutively present in a 
latent monomeric form, is activated by binding to 2-5A. Activated RNase L cleaves 
single stranded viral and cellular RNA molecules, thus inhibiting viral replication. 
 
ADAR1: RNA-specific Adenosine Deaminase  
ADAR1 is an interferon inducible RNA editing enzyme that targets cellular and 
viral double stranded RNAs (41). ADAR1 catalyzes the deamination of an adenosine to 
an inosine. The resultant I-U mismatch could potentially destabilize the structure of 
RNA. Furhter, inosine is recognized as a guanosine by the transcription and translation 
machinery of the cell, causing an A-U to G-C mutation in the genome. This system is 
used by the host to increase the diversity of certain neuron receptors, however in the 
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context of the virus, this could have a deleterious effect on the function of the viral 
protein. A-I modifications, the result of ADAR1 activi y, have been observed in the 
genomes of multiple viruses (13). 
 
Mx GTPases 
The Mx family of GTPases belongs to the superfamily of large dynamin-like 
GTPases (167). These interferon-inducible GTPases are very powerful anti-viral agents. 
Knockout mice that lacked the IFN α/β receptor but were transgenically expressing the 
human MxA protein, showed resistance to a variety of viruses, indicating that MxA alone 
could provide resistance to viral infections, without any of the other interferon- inducible 
proteins (53). The GTPase activity resides in the N-t rminus of the protein and is 
required for anti-viral function. Via the C-terminus, this protein self-assembles into large 
oligomeric complexes. It is thought that in the presence of viral infection, the C-terminus 
forms aggregates with nucleocapsid structures of the virus, thus blocking access of the 
nucleocapsid proteins from the rest of the cellular m chinery. Although humans encode 
two IFN-inducible Mx proteins, MxA and MxB, only the former was shown to have anti-
viral function. The MxA protein has been shown to endow resistance to a variety of 
human viruses including bunyaviruses, togaviruses, orthomyxoviruses, paramyxoviruses, 





Human P56 (HuP56), along with HuP54, HuP58 and HuP60 are a family of 
structurally related proteins that are up-regulated by IFNα and β, double-stranded RNA 
and virus infections. These proteins have multiple tetratrichopeptide (TPR) repeats, but 
no other identifiable motif throughout their lengths. These 34 amino acid TPR repeats are 
found in a number of other proteins where they interact with multi-protein complexes 
(17). The HuP56 protein binds to the eIF3e subunit of the eukaryotic translation initiation 
factor 3, which is a complex of 11 subunits (47). This inhibits the function of eIF3 and 
down regulates translation, thus blocking viral replication. HuP56 was shown to block 
translation from the IRES element in hepatitis C virus (180). 
Some of the ISGs described above, PKR, MxA, HuP54, HuP56, HuP58 and 




CHAPTER 2: MATERIALS AND METHODS 
Cell culture, plasmids and antibodies 
HeLa, 293 and 293T cells were grown in Dulbecco's modified Eagle's medium 
(Cellgro, Mediatech, Inc) supplemented with penicillin-streptomycin and 10% fetal 
bovine serum. High5 cells were grown in Grace’s insect cell medium (Biowhittaker, 
Lenzo), supplemented with penicillin-streptomycin and 5% fetal bovine serum. 
Constructs for expression of Ube1L, UbcH8, and ISG15 were described previously. A 
plasmid containing the complete Herc5/CEB1 open reading frame with a Myc-tag, was 
provided by M. Ohtsubo (Hiroshima University). The H rc5 open reading frame and 
mutants were subcloned into a pcDNA3 vector containing an amino-terminal tandem 
affinity purification tag (pcNTAP) or an amino-terminal HA tag. A full-length clone for 
Herc6 was provided by R. Kroismayr (Medical University of Vienna) and was sub-
cloned to bear an N-terminus TAP-tag as well as an HA tag. A plasmid coding for 
IQGAP1 was provided by Dr. Martin Poenie (The University of Texas at Austin). Full 
length IQGAP1 as well as truncation mutants were sub-cloned into pcNTAP vector.  A 
baculo-virus expression construct for purifying His-tagged IQGAP1 was provided by 
George Bloom (University of Virginia).  
Anti-p56 antibody was provided by Ganes Sen (Cleveland Clinic), anti-MxA 
antibody by Otto Haller (University of Freiburg), and ISG15 antibody by Ernest Borden 
(Cleveland Clinic). Monoclonal anti-IQGAP1 antibody was purchased from BD 
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Biosciences. An antibody to detect V5-tagged proteins was purchased from AbD Serotec. 
Anti-flag M2 antibody was obtained through Sigma and the HA.11 monoclonal antibody 
through Covance. PAP (peroxidase-anti-peroxidase) antibody (Rockland 
Immunochemicals for Research) was used to detect TAP-tagged proteins.  
 
siRNA and DNA Transfections 
siRNAs were purchased from Dharmacon or Invitrogen. Wherever mentioned, the 
‘smartpool’ of siRNAs from Dharmacon was used to target genes. The smartpool is a 
mixture of four siRNAs designed to target four different sequences within a gene. The 
sequences of the siRNAs of a Smartpool were not disclosed. Either Oligofectamine 
(Invitrogen) or X-treme transfect (Roche) was used to transfect siRNAs at a final 
concentration of 20 nM or 100 nM, as indicated in each experiment. Cells were subjected 
to siRNA treatment for 56-72 hrs. The sequences of siRNAs used in this study are given 
in Table 1.  
DNA transfections were done in 6-well or 12-well plates, using either Genejuice 
(Novagen) or Lipofectamine 2000 (Invitrogen).  Cells were harvested 48 hrs post-
transfection. For large scale transfections involving 10cm plates, the calcium chloride 
method (46, 182) was followed.  
 
Reverse Transcriptase (RT)-PCR and Microarray Analyses 
Total RNA for RT-PCR was isolated using the PARIS kit (Ambion, Inc.). 
SuperscriptII reverse transcriptase (Invitrogen) was used for cDNA synthesis, which was 
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used as a template in subsequent PCR reactions. Initially, a range of PCR cycles was 
performed using cDNA from IFN-β-treated or untreated cells to determine the linear 
range of amplification for each gene, and these parameters were used for PCR. 
Microarray analyses were performed as described previously (93). Elements chosen for 
analysis were screened for several data quality standards, including minimum intensity 
and pixel consistency. 
 
Detection of ISG15 conjugates 
siRNA transfections were carried out as described above. 12-24 hrs post-
transfection, cells were treated with IFN-β (1,000 units/ml; Berlex) for an additional 48 
hours. Cells were then harvested and lysed in 1% NP-40 buffer (100 mM NaCl, 100 mM 
Tris pH 7.5, 1% Nonidet P-40, 1 mM Dithiothreitol, 10µg/ml Aprotinin, 1 µg/ml 
Leupeptin and 10 µg/ml PMSF). 30 µg of total cell extract was separated on an SDS-
PAGE, transferred to a nitrocellulose membrane and probed with anti-ISG15 antibodies 
to view total cell conjugates.    
Alternatively, 12-24 hours after the siRNA treatment, cells were transfected with 
plasmids expressing Ube1L (0.125 µg), UbcH8 (0.125 µg) and HA/Flag-tagged ISG15 
(0.25 µg), with or without Herc5 expressing plasmids (0.25 µg). When other E3s were 
tested, they were transfected at the same concentratio s (0.25 µg). 48 hours post-
transfection, cells were harvested. 30 µg of total cell extract was separated on an SDS-
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PAGE, transferred onto a nitrocellulose membrane and probed with anti-HA or anti-Flag 
antibodies to detect ISG15 and its conjugates.  
To detect ISG15 conjugates of individual substrates, plasmids expressing tagged 
substrates (0.25 µg) were co-transfected into cells along with Ube1L, UbcH8 and ISG15, 
with or without Herc5. In the case of 3X-flag p56, extracts were run on an SDS-PAGE 
and probed with M2-flag antibodies to detect p56 and its conjugated form. For V5-
moesin and V5-TrxR1, extracts were subjected to immuno-precipitation using anti-V5 
antibody and the precipitated proteins were then separated on an SDS-PAGE followed by 
western blotting with anti-V5. To detect ISG15 conjugates of interferon-induced 
substrates, cells were harvested 48 hrs post-interferon treatment and extracts were 
immunoblotted with either p56 or MxA antibodies.  
Auto-conjugation of Herc5 and Herc6 was observed by transfecting TAP-tagged 
versions of the E3s along with Ube1L, UbcH8 and ISG15 and subjecting the extracts to 
immuno-blotting with anti-TAP antibodies.   
In the case of IQGAP1, 10cm plates of 293T cells were transfected with a TAP-
tagged construct of IQGAP1 along with plasmids exprssing Ube1L, UbcH8, and ISG15 
with or without Myc-tagged Herc5. 48 hours post-transfection, cells were harvested in 
400 µl 1% NP40 buffer and lysates were bound to IgG-sepharose beads (GE Healthcare) 
for two hours. Beads were washed in 0.1% NP40 buffer, resuspended in 1X SDS buffer 
and loaded on a denaturing PAGE. Separated proteins were transferred onto a 
nitrocellulose membrane, and probed with anti-TAP antibody to detect IQGAP1 and 
IQGAP1 conjugated to ISG15. 
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Purifying Ube1L , UbcH8 and IQGAP1 from Insect cells 
Baculo-virus constructs expressing GST-tagged Ube1L or UbcH8 were used to 
infect High-5 insect cells. 48 hours after infection, cells were harvested, lysed in 1% NP-
40 buffer, and extracts were bound to glutathione-sepharose beads (Novagen) for 3 hours 
at 4 oC. Beads were washed with 1X PBS, 1% Triton-X and resuspended in precision 
protease cleavage buffer (Tris pH 7.5 25 mM, NaCl 50 mM, 0.1% Triton-X, 1 mM 
Dithiothreitol, 1 mM EDTA). The beads were incubated overnight with 2 units of 
precision protease (GE Healthcare) and the purified enzymes were obtained in the 
supernatant. A baculo-virus expression construct for purifying His-tagged IQGAP1 was 
provided by George Bloom (119). Wild type IQGAP1 was purified on a Ni-NTA His 
Bind Resin (Novagen), as per manufacturer’s protocol. 
  
Preparation of 32P-labelled ISG15 
The pGEX6p plasmid (GE Healthcare) was modified to include a cAMP-
dependent kinase phosphorylation site immediately downstream of the precision protease 
cleavage site and upstream of the multiple cloning s te. The ISG15 open-reading frame 
was then cloned into this construct. The GST-ISG15 fusion protein was expressed in 
Escherichia coli DH10β and purified by standard methods on glutathione sepharose. The 
beads were resuspended in cAMP-dependent kinase reaction buffer (40 mM Tris pH 7.5, 
20 mM magnesium acetate) and incubated with 158 units of cAMP-dependent kinase 
(Promega) and 20 µCi of 32P-γ-ATP for one hour at room temperature. Excess gamma 
32P-γ -ATP was washed off with 1XPBS and the beads were incubated overnight with 2 
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units of precision protease in its appropriate buffer. 32P-labeled ISG15 was recovered in 
the supernatant. 
 
In-vitro  ISG15 conjugation assays 
In vitro ISG15 conjugation assays were performed in the presence of 10 mM Tris 
pH 7.5, 50 mM NaCl, 7.5 mM ATP, 10 mM MgCl2, and 0.1 mM DTT. Ube1L, UbcH8 
and 32P-labeled ISG15 were prepared as described above. Extracts of 293T cells 
transfected with Herc5 or its C-A mutant, were used as the source of E3. In some cases, 
extracts of IFN-β-treated HeLa cells were substituted as the E3 source. Purified E1, E2 
and labeled ISG15 were incubated in the reaction buffer at room temperature for 30 min, 
with or without the E3. Purified E6AP was used as a positive control in these assays. 
Reactions were stopped by adding 1X SDS-PAGE loading buffer without DTT to detect 
thioester bonds, or with DTT to detect substrate conjugation. Products were run on an 
SDS-PAGE and visualized by autoradiography. 
 
In vitro  protein interaction assays 
Plasmids expressing TAP-tagged Herc5 or various mutants of Herc5 were 
transfected in 10cm plates of 293T cells. 48 hrs post-transfection, cells were lysed in 1% 
NP-40 buffer and extracts were bound to IgG-sepharose beads for 2 hrs at 4 0C. Beads 
were washed in 0.1% NP-40 buffer and the bound TAP-tagged Herc5 proteins were 
assayed for binding to purified IQGAP1. Reactions were carried out in Tris pH 7.5 25 
mM, NaCl 50 mM and 0.2% NP-40 at 4 oC for 2 hrs. Beads were subsequently washed in 
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0.1% NP-40 buffer and resuspended in 1X SDS-PAGE loading buffer. IQGAP1 was 
detected by immunoblotting. 
 
In vivo IQGAP1-Herc5 binding assays 
Wild type IQGAP1 and truncation mutants were expressed as TAP fusions, along 
with Myc-tagged Herc5, in 10 cm plates of 293T cells. 48 hrs post-transfection, cells 
were lysed in 1% NP-40 buffer, diluted in TRIS 25 mM, NaCl 50 mM buffer, and 
extracts were bound to IgG-sepharose beads for 2 hrs at 4 0C. Beads were washed in 
0.1% NP-40 buffer and loaded on an SDS-PAGE. Bound Herc5 was detected by 







































11 Smartpool IQGAP1 (B) 
12 Smartpool TRIM22 
13 Smartpool TRIM25 
 
 
Table 1: Sequences of siRNAs used for this research. 
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Wild type Herc5 cloned in pcDNA3 with different tags.  
CS2 + MT CEB1 Wild type Herc5 cloned in pCS2 + MT (Myc-Tag). 
Provided by M. Ohtsubo (Hiroshima University). 
pcNTAP Herc5 C-A C994A mutant of Herc5 cloned in pcNTAP. 
pcNTAP Herc5 ∆F Last two amino acids of Herc5 (FG) were deleted.  
pcNTAP Herc5 C5-6 Last amino acid of Herc5 (G) was replaced by the last 8 
amino acids of Herc6 (VSPMLTQS).  
pcNTAP Herc5 HECT HECT domain of Herc5 (aa 686 – 1024) cloned in 
pcNTAP. 
pcNTAP Herc5 RCC Herc5 residues 1-380 cloned in pcNTAP. 
pcNTAP Herc5 ∆RCC Herc5 residues 381-1024 cloned in pcNTAP. 
pcNTAP Herc5 ∆150 Herc5 residues 157-1024 cloned in pcNTAP. 
pcNTAP Herc5 ∆100 Herc5 residues 101-1024 cloned in pcNTAP. 
pcNTAP Herc5 ∆SBB Herc5 deleted of residues 554-579, cloned in pcNTAP. 
pcNTAP Herc6 
pcHA Herc6 
Wild type Herc6 cloned in pcDNA3 with different tags. 
pcNTAP Herc6 C-A C985A mutant of Herc6 cloned in pcNTAP. 
pcNTAP Herc 5/6 Herc5 with Herc6 HECT domain cloned in pcNTAP. 
pcNTAP Herc 6/5 Herc6 with Herc5 HECT domain cloned in pcNTAP.  
pcNTAP Herc4 
pcFLAG Herc4 
Wild type Herc4 cloned in pcDNA3 with different tags. 
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pcNTAP TRIM25 (EfP) Wild type TRIM25/Efp cloned in pcNTAP. 
pcHA-NTAP E6AP Double-tagged E6AP cloned in pcDNA3. 
pcHA ISG15 HA-tagged ISG15 cloned in pcDNA3. 
His-3X-FLAG-ISG15 Double-tagged ISG15 cloned in pcDNA3. Provided by 
Zhao C (Krug Lab). 
His-3X-FLAG-p56 Double-tagged HuP56 cloned in pcDNA3. Provided by 
Zhao C (Krug Lab). 
V5-Moesin V5-tagged Moesin cloned in pcDNA3. Provided by 
Zhao C (Krug Lab). 
V5-TrxR1 V5-tagged TrxR1 cloned in pcDNA3. Provided by Zhao 
C (Krug Lab). 
pGEX2T-IQGAP1 Wild type IQGAP1 cloned in pGEX2T. Provided by Dr. 
Martin Poenie (Univ. of Texas at Austin). 
pGEX6p IQGAP1 Wild type IQGAP1 cloned in pGEX6p. 
pcNTAP IQGAP1 TAP-tagged IQGAP1 cloned into pcDNA3. 
pcNTAP IQ 1001-1657 IQGAP1 residues 1001-1657 cloned into pcNTAP. 
pcNTAP IQ 1-525 IQGAP1 residues 1-525 cloned into pcNTAP. 
pcNTAP IQ 526-1657 IQGAP1 residues 526-1657 cloned into pcNTAP. 
 
 
Table 2: List of plasmids used in this study.
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CHAPTER 3: HERC5, AN INTERFERON -INDUCED HECT E3 
ENZYME , IS REQUIRED FOR CONJUGATION OF ISG15 IN 
HUMAN CELLS  
 
3.1 Introduction 
Type 1 interferons play an essential role in innate immunity. One of the many 
genes strongly activated by IFN-α/β encodes ISG15, a 17-kDa ubiquitin-like protein 
(Ubl) (31, 48). Like ubiquitin (Ub), Ubls are linked to target proteins via isopeptide 
bonds between their terminal carboxyl group and lysine ide chains of target proteins 
(75). The fact that ISG15 is expressed and conjugated in IFN-α/β stimulated cells and 
lipopolysaccharide-stimulated cells implies that ISG15 conjugation is likely to be a 
component of the innate immune response. This is supported by the finding that ISG15 
knockout mice are more susceptible to infections of influenza virus, herpes simplex virus 
and Sindbis virus (106) and the NS1 protein of influenza B virus blocks ISG15 
conjugation (193).  
The biochemical effect of ISG15 on target proteins is unknown, however the 
recent identification of a large number of target proteins (197) provides opportunities for 
determining both the function of ISG15 and its role in the innate immune response. Also 
essential for functional studies is the identification of the complete set of enzymes 
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required for ISG15 conjugation. As with Ub conjugation, it is presumed that a 
cooperating set of E1, E2, and E3 enzymes, in addition to possible accessory factors, will 
be required for ISG15 conjugation. The ISG15 E1 and E2 enzymes have been identified. 
Ube1L is a single-subunit enzyme 62% similar to the Ub E1 enzyme (193), and UbcH8 is 
the major, if not exclusive, E2 enzyme for ISG15 (196). The genes encoding both Ube1L 
and UbcH8 are, like ISG15, transcriptionally activated by IFN-α/β (193, 196), suggesting 
that the entire conjugation system might be coordinately regulated.  
A candidate E3 enzyme for ISG15 conjugation emerged from mass spectrometry-
based identification of ISG15 target proteins (197). Proteomics analyses of SUMO- and 
Ub-conjugated proteins have shown that enzymatic components of Ub/Ubl conjugation 
pathways are often auto-conjugated (21, 145), and co sistent with this, Ube1L and 
UbcH8 were identified as ISG15-modified proteins. In addition, a single HECT E3, 
Herc5, was identified as an ISG15-modified protein, suggesting that this enzyme might 
also be a component of the ISG15 conjugation pathway.  
Further, Herc5 belongs to the HECT family of E3 enzymes (70), some of which 
can functionally interact with UbcH8 (102, 196). We d monstrated previously that Rsp5, 
an essential HECT E3 of Saccharomyces cerevisiae, can interact with UbcH7 and UbcH8 
in vitro, and can also catalyze Ube1L- and UbcH8-dependent conjugation of ISG15 in 
vitro (196).  Similarly, human E6AP, which also functions with UbcH7 and UbcH8, can 
catalyze conjugation of ISG15 to p53 in the presence of the human papillomavirus E6 
protein in vitro (S. Beaudenon and J. M. H., unpublished results).  While there is no 
evidence to suggest that either E6AP or human homolgs of Rsp5 normally function in 
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the ISG15 pathway in vivo, these experiments predicted that bona fide ISG15 E3 
enzymes might share conserved functional domains and mechanisms with Ub E3 
enzymes.   
The genes for Ube1L and UbcH8 were, like ISG15, upregulated by IFN-β and it 
was proposed that the entire ISG15 conjugating machinery might be coordinately 
regulated. Microarray gene expression experiments revealed that Herc5 and a closely 
related gene Herc6, were the only two HECT E3s induce  by interferon and, together 
with the other evidence stated above, I hypothesized that Herc5 might be involved in 
ISG15 conjugation.  
I show here that Herc5 is required for the conjugation of ISG15 to a broad 
spectrum of target proteins in vivo. siRNAs targeting Herc5 show a dramatic decrease in 
overall ISG15 conjugation in human cells, abrogating conjugation to the vast majority of 
ISG15 target proteins in vivo. Further, wild-type Herc5, but not its C994A mutant, 
enhances substrate conjugation when co-expressed with Ube1L, UbcH8 and ISG15 in 
non-IFN treated cells. I also demonstrate that wild type Herc5, but not the catalytically 
inactive C994A mutant, can auto-conjugate ISG15 in vivo, and extract of cells transfected 
with wild type Herc5 support ISG15 conjugation in vitro. Together, these results indicate 




 siRNAs against Herc5 lead to a decrease in ISG15 conjugates in IFN-β-treated cells  
Herc5 is one of six human Herc proteins (HECT and RCC1), defined by a 
carboxyl-terminal HECT domain and by one or more RLDs (RCC1-like domains) (59). 
Herc5 was a candidate for being a component of the ISG15 conjugation pathway based 
on the fact that it was identified as an ISG15-modifie  protein (197), and it belongs to the 
HECT family of E3 enzymes, some of which can interact with UbcH8 (102, 196). To 
determine whether Herc5 plays a significant role in overall ISG15 conjugation, two 
synthetic double-stranded siRNAs (designated 5A and 5B) were designed to target Herc5 
mRNA. The Herc6 protein is 49% identical to Herc5, and two siRNAs (6A and 6B) were 
therefore designed to target Herc6, as well as one siRNA that would simultaneously 
target both Herc5 and Herc6 (5/6). RT-PCR confirmed that transfection of the Herc5- and 
Herc6-specific siRNAs reduced Herc5 and Herc6 mRNA levels, respectively, in IFN-β
treated HeLa cells (Fig 3.1A).  
Because a Herc5-specific antibody was not available, we took advantage of our 
epitope-tagged (HA and TAP) Herc5 expression vectors t  confirm that all three Herc5 
siRNAs effectively knocked-down Herc5 at the protein l vel (Fig 3.1B). The 5A, 5B, and 
5/6 siRNAs resulted in a dramatic reduction of HA-Herc5 protein, while neither of the 
Herc6 siRNAs, an siRNA against E6AP nor a UbcH8-specific siRNA, affected HA-
Herc5 protein levels. Only the E6AP-specific siRNA affected the level of the endogenous 
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E6AP HECT E3. Fig 3.1C shows that siRNAs against Herc6 ffectively lowered the 
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Figure 3.1 Herc5 and Herc6 siRNAs are effective at the mRNA as well as protein 
levels. A) RT-PCR analysis to determine the effects of siRNAs on Herc5, Herc6, 
and GAPDH (glyceraldeyde-3-phosphate dehydrogenase) mRNA levels in IFN-
β-treated HeLa cells. Cells were transfected with siRNA targeting either Herc5 
(5A, 5B), Herc6 (6A, 6B), or both Herc5 and Herc6 (6/5). Total RNA was 












            




































siRNA: - - 5A      5/6       6A    E6AP
TAP-Herc6: - +         +         +         +         +
Herc6
E6AP
Anti-TAP (Herc6) and Anti-E6AP
Figure 3.1 HeLa cells were transfected with the indicated siRNAs. Eight hours 
later, they were transfected with a plasmid expressing HA-tagged Herc5 (B) or 
TAP-tagged Herc6 (C). Cell extracts were prepared after n additional 48 h, and 
an immunoblot was performed with anti-HA antibody (B) or anti-TAP antibody 
(C) to detect levels of Herc5 and Herc6, respectively. E6AP was used as a control 




HeLa cells were transfected with the Herc5 or Herc6 siRNAs or, as a negative 
control, an siRNA against the E6AP HECT E3 (93). Six hours after transfection, IFN-β 
was added for an additional 48 hrs. Total cell extracts were prepared and ISG15 
conjugates were analyzed by immunoblotting with an antibody against ISG15. Induction 
of ISG15 and high molecular weight ISG15 conjugates wa  observed in IFN-β treated 
cells (Fig 3.2, compare lanes 1 and 2). Both of the Herc5-specific siRNAs and the siRNA 
that targeted Herc5 and Herc6 (5/6) resulted in a dramatic decrease in overall ISG15 
conjugates (lanes 3–5), while neither of the Herc6-specific siRNAs or the E6AP siRNA 
led to a discernible decrease in ISG15 conjugates (lanes 6–8).  
 









































Figure 3.2 siRNAs against Herc5 
lead to a decrease in ISG15 
conjugates. HeLa cells were mock-
transfected (lanes 1 and 2) or 
transfected with the indicated 
siRNAs and then treated with IFN-β 
for 48 h or left untreated (lane 1). 
l Article">17</ref-
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Combinations of Herc5 and Herc6 siRNAs were also transfected together, on the 
premise that potential Herc6-dependent effects might be more evident following 
reduction of Herc5 activity (Fig 3.3). For these exp riments, a third Herc5 siRNA (5C) 
was used that elicited only a partial reduction in Herc5 activity (compare lanes 1–3). Co-
transfection of Herc6 siRNA 6A with either Herc5 siRNA 5A or 5C did not elicit any 
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Anti-ISG15
Figure 3.3 Co-transfection of Herc5-
Herc6 siRNAs did not lead to a further 
decrease in ISG15 conjugates. HeLa 
cells were mock-transfected (lane 1) or 
transfected with individual Herc5 or 
Herc6 siRNAs (lanes 2, 3 and 6) or 
combinations of Herc5 and Herc6 
siRNAs (lanes 4 and 5), and then 
treated with IFN-β for 48 hrs. Cell 
extracts were prepared and analyzed by 
immunoblotting with ISG15 antibody. 
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The effect of Herc5 siRNAs on conjugation of ISG15 to two specific target 
proteins, p56 and MxA, was also examined (Fig 3.4). Both these proteins are induced by 
IFN-β, and are anti-viral proteins (162). p56 binds to eIF3 and inhibits translation of viral 
proteins (47) and MxA is a large GTPase that inhibits viral replication (49). The 
identification and validation of the IFN-β -induced ISG15-conjugated forms of both of 
these proteins was described previously (197). Consistent with the effect of Herc5 
siRNAs on total ISG15 conjugates, siRNAs that targeted Herc5 blocked conjugation to 
both p56 and MxA, while Herc6-specific siRNAs did not. We conclude that Herc5 plays 
a major role in mediating overall ISG15 conjugation t  a broad spectrum of target 
proteins. Given that it is interferon-induced, it is possible that Herc6 might also function 
in the ISG15 conjugation pathway, but if so, it clear y plays a minor role relative to 
Herc5.  
siRNA:

















1       2       3         4        5        6    
Anti-p56 (upper panel)
Anti-MxA (lower panel)
Figure 3.4 siRNAs against Herc5 
block ISG15 conjugation of p56 
and MxA. HeLa cells were mock-
transfected (lane1) or transfected 
with siRNAs as shown and then 
treated with IFN-β for 48 hrs. Cell 
extracts were immunoblotted with 
antibodies against p56 and MxA. 
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Herc5 is induced by interferon-beta 
The genes encoding ISG15, Ube1L, and UbcH8 are transc iptionaly induced in 
response to interferon signaling. We therefore determined whether expression of Herc5 
and/or Herc6 was regulated by IFN-β by microarray gene expression analyses, comparing 
IFN-β-treated cells to untreated cells at various time points following addition of IFN-β 
(3, 6, and 21 h). Fig 3.5A shows representations of the microarray elements 
corresponding to ISG15, Ube1L, UbcH8, Herc5, and Herc6 cDNAs, along with elements 
corresponding to three genes not expected to be affected by IFN-β treatment (E1Ub, 
UbcH7, and E6AP). The induction of ISG15, Ube1L, and UbcH8 was evident, along with 
both Herc5 and Herc6, with maximal induction over this time course at 21 h post-IFN-β 
treatment. This corresponds to the beginning of maxi l accumulation of ISG15 
conjugates (112). Expression of E1Ub, UbcH7, and E6AP was not affected by IFN-β 
treatment. The results from micro-array analysis were confirmed by RT-PCR. Fig 3.5B 
shows that Herc5 and Herc6 are induced by IFN-β at the mRNA level. 
The time course and magnitude of Herc5 and Herc6 induction was similar to that of 
Ube1L and UbcH8 (Fig 3.5C). The regulation of Herc5 and Herc6 expression by IFN-β is 
consistent with the demonstrated importance of Herc5 in ISG15 conjugation, as well as a 
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Figure 3.5 Herc5 and Herc6 expression is induced by interferon-β. (Figure legend on 
next page) 









0         3            6         21
 
61 
            C. 
 
Figure 3.5 Herc5 and Herc6 expression is induced by interferon-β. A) RT-PCR 
analysis. Total RNA was prepared from non-interferon-treated and interferon-
treated HeLa cells. RT-PCR was performed using Herc5 and Herc6–specific 
primers.  B) Microarray gene expression analysis waperformed, comparing 
HeLa cells treated with IFN-β for the indicated time periods (0, 3, 6, and 21 h) to 
untreated HeLa cells. cDNA from IFN-β-treated and untreated cells were labeled 
with Cy5 (red) and Cy3 (green), respectively. Microarray elements corresponding 
to the indicated genes are shown. C) Bar graph repres ntation of the microarray 
data shown in B, illustrating the time course and magnitude of induction for each 





















Herc5 boosts ISG15 conjugation in non-IFN-treated cells 
Co-transfection of plasmids expressing ISG15, Ube1L, and UbcH8 leads to 
ISG15 conjugation in non-IFN-treated HeLa cells, although at a lower level than 
observed in IFN-β-treated cells. To determine whether this level of conjugation was due 
to a significant basal level of Herc5 expression, I transfected Herc5 siRNAs prior to co-
transfection of plasmids expressing ISG15, Ube1L, and UbcH8. As shown in Fig 3.6, 
transfection of Herc5 siRNAs (5A, 5B, or 5/6) did indeed block ISG15 conjugation, 
while Herc6 siRNAs did not, indicating that a basal level of Herc5 expression is 
responsible for ISG15 conjugation in this context. This is consistent with my finding that 
RT-PCR of the Herc5 gene from non-interferon induce lls shows a low level of Herc5 
mRNA present in these cells (Fig 3.5A).   
 
 
siRNA: 5A 5B 6A5/6 E6AP-
FLAG-
ISG15
1        2      3      4       5       6
Anti-FLAG (ISG15)
Figure 3.6 Basal level of Herc5 is 
responsible for ISG15 conjugation in non-
interferon-treated cells transfected with E1, 
E2 and ISG15. Cells were first transfected 
with the indicated siRNAs and then 
transfected with plasmids expressing FLAG-
ISG15, Ube1L, and UbcH8. Cell extracts 
were prepared and an immunoblot performed 
with anti-FLAG antibody.  
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I also determined whether co-transfection of a Herc5-expressing plasmid would 
enhance the level of ISG15 conjugates seen in non-IFN-treated cells. In both HeLa cells 
(Fig 3.7) and 293T cells (data not shown), transfection of a Herc5-expressing plasmid 
boosted ISG15 conjugation ~5-fold over that seen with transfection of ISG15, Ube1L, 
and UbcH8 plasmids. I constructed a Herc5 mutant in which the catalytic cysteine residue 
in the HECT domain was replaced by an alanine (C-A). This conserved cysteine residue 
is a hallmark of HECT type E3s and has been shown t form a thioester bond with 
ubiquitin prior to transferring it to the substrate. Importantly, the Herc5 active-site mutant 
(C994A) did not stimulate ISG15 conjugation, indicating that the catalytic activity of 
Herc5 is required for its function in the ISG15 system. Herc6 was also co-transfected 
along with the E1, E2 and ISG15 expressing plasmids. There was no change in the levels 
of ISG15 conjugates in the presence or absence of Hrc6, again indicating that Herc6 
































Figure 3.7 Herc5 boosts ISG15 
conjugation in non-interferon-treated 
cells. HeLa cells were either mock-
transfected (lane 5) or transfected with 
plasmids expressing FLAG-ISG15, 
Ube1L, and UbcH8, without Herc5 
(lane 1) or with co-transfection of 
plasmid expressing wild type Herc5 
(lane 2) or the active-site C994A 




I examined the levels of ISG15 conjugates of two individual targets, p56 and 
Moesin, in the presence and absence of transfected Herc5. As mentioned above, p56 is a 
protein with anti-viral function. Moesin connects plasma-membrane proteins to actin 
filaments and is involved in mediating cytoskeletal changes (126), and it was recently 
shown to have anti-retroviral activity (133). HeLa cells were transfected with Ube1L, 
UbcH8, ISG15 and Herc5, along with FLAG-tagged p56 or V5-tagged moesin. 
Conjugation of both substrates to ISG15 was enhanced wh n wild type Herc5, but not the 
C994A mutant, was included (Fig 3.8, compare lanes 3 v  4 and lanes 7 vs 8), confirming 
the results seen with overall ISG15 conjugation. Also, Herc6 did not boost ISG15 
conjugation to either of these substrates. 
UbcH8 is the only E2 enzyme known to function in ISG15 conjugation (196), and 
as expected, Herc5-dependent stimulation of ISG15 conjugation was not evident upon co-
transfection with UbcH7 (Fig 3.9, lanes 2 and 5). In addition, a single amino acid 
mutation at residue 62 of UbcH8 (F62A) abrogated Herc5-dependent ISG15 conjugation. 
F62 of UbcH8 represents a conserved residue among E2 proteins that have been shown to 
interact with HECT E3s (e.g. UbcH5 isoforms, UbcH6, UbcH7, UbcH8), and both 
biochemical and structural experiments have indicated that this residue is critical for the 
ability of E2s to interact with the HECT domain (68, 139). The fact that the F62A 
mutation of UbcH8 abrogated Herc5-dependent ISG15 conjugation is consistent with a 





Figure 3.8 Herc5 boosts ISG15 conjugation of Moesin and p56 in non-interferon-treated 
cells. HeLa cells were transfected with V5-Moesin (left panel) or 3X-FLAG p56 (right 
panel), along with plasmids expressing Ube1L, UbcH8, ISG15 and no Herc5 (lanes2 and 
6) or wild type Herc5 (lanes 3 and 7) or the C994A mutant (lanes 4 and 8). Cell extracts 
were prepared and immunoblots were probed with anti-V5 antibody (left panel) or anti-






























































































1        2        3       4        5
Anti-FLAG (ISG15)
Figure 3.9 UbcH8, but not UbcH7, functions with Herc5 in vivo. 293 cells 
were transfected with plasmids expressing FLAG-ISG15, Ube1L, and UbcH8, 
without (lane 2) or with co-transfection of plasmid expressing wild-type Herc5 
(lanes 3). Plasmids expressing the F62A UbcH8 mutant or UbcH7 were used 
in place of UbcH8 plasmid in lanes 4 and 5, respectiv ly. Cell extracts were 
immunobloted with anti-FLAG antibody. 
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TRIM25 (EfP) does not affect overall ISG15 conjugation 
Micro-array analysis showed that, in addition to Herc5 and Herc6, six other 
ubiquitin ligases were transcriptionally up-regulated by IFN-β. They all belong to the 
Tripartite Motif (TRIM) family of proteins, which are characterized by the presence of a 
RING domain, one or more B-box motifs and a coiled coil domain. Some of the TRIM 
members have RING-domain-dependent ubiquitin ligase activity (122), and at least one 
of these, TRIM25 (or Efp), has been shown to interact with UbcH8 (175). I determined 
whether TRIM25 might be involved in ISG15 conjugation, using similar approaches as 
described above for Herc5 and Herc6. A set of four siRNAs were designed to target 
TRIM25 (Smartpool from Dharmacon), and cells were transfected with a common mix of 
all four at a final concentration 100 mM. Figure 3.10 shows that the siRNAs efficiently 
knocked down TRIM25 at the protein level. Cells were transfected with the TRIM 25 
siRNAs, followed by IFN-β-treatment for 48 hours. As seen in figure 3.11, knoc down 
of TRIM25 did not affect overall ISG15 conjugation. Further, TRIM25 did not enhance 
ISG15 conjugation when co-transfected with Ube1L, UbcH8 and ISG15 (Fig 3.12). 
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Figure 3.10 siRNAs against TRIM25 are effective at the protein level. HeLa cells 
were either mock transfected (lane 2) or transfected with siRNAs as indicated, and 
then transfected with TAP-tagged TRIM25. Cell extracts were immunoblotted with 
anti-TAP antibody to detect TRIM25 or anti-tubulin a tibody as a control. 
Figure 3.11 siRNAs against TRIM25 do not affect overall ISG15 conjugation. HeLa 
cells were either mock transfected (lane 2) or transfected with siRNAs against Herc5 
or TRIM25 or TRIM22 and then treated with IFN-β for 48 hrs. Cell extracts were 
immunoblotted with anti-ISG15 antibody.  















































Figure 3.12 TRIM25 does not boost ISG15 conjugates in non-interferon-
treated cells. HeLa cells were transfected with plasmids expressing Ube1L, 
UbcH8, FLAG-ISG15 with no Herc5 (lane 1) or with plasmids expressing 





























1      2      3       4      5
 
70 
Herc5 is auto-conjugated to ISG15 
A common feature exhibited by many ubiquitin E3 enzymes is auto-
ubiquitination. The physiological significance of this phenomenon is not always known. 
For certain ligases, auto-ubiquitination leads to degradation and hence down-regulation 
of the E3 activity, as is the case with Mdm2 (29, 63). In other cases, auto-conjugation is 
required for activating downstream events, as seen with K-63 linked auto-ubiquitination 
of TRAF6 (104). Herc5 was one of the proteins identified in the ISG15 proteomics assay 
and I determined whether this was a result of auto-conjugation. Extracts of cells 
transfected with plasmids expressing Ube1L, UbcH8, ISG15 and TAP-Herc5 were 
probed with anti-TAP antibodies. High molecular weight ISG15-dependent conjugates of 
Herc5 were detected (Fig 3.13). No conjugates were obs rved when ISG15 was not 
included in the transfection mix (Fig 3.13, lane 2), ruling out the possibility that Herc5 
might be auto-conjugated to ubiquitin. The majority of conjugates were detected only 
when UbcH8 was co-transfected (Fig 3.13, lanes 3 and 4). The small number of 
conjugates seen in the absence of transfected UbcH8 is likely due to the low levels of 
endogenous UbcH8. Further, the catalytically inactive C994A mutant of Herc5 was not 
modified, confirming that the conjugates were a result of auto-conjugation (Fig 3.13, 











































Figure 3.13 Herc5 is auto-conjugated to ISG15 in vivo. HeLa cells were transfected 
with wild type TAP-tagged Herc5, with or without ISG15 (lanes 1 and 2), and with 
or without UbcH8 (lanes 3 and 4).  The C994A mutant was also transfected with 
or without UbcH8 (lanes 5 and 6). Cell extracts were prepared and immunoblotted 
with anti-TAP antibody to detect Herc5. 
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In-vitro assays for ISG15 conjugation 
In order to demonstrate ISG15 conjugation activity of Herc5 in vitro, I purified 
each of the components of the ISG15 machinery. Ube1L and UbcH8 were expressed as 
GST-fusion proteins in insect cells and purified on glutathione-sepharose beads by 
standard methods. ISG15 was expressed and purified f om bacteria and labeled with 32P-
γ-ATP (see materials and methods). Herc5 did not express well in bacteria, and no 
activity was detectable when the protein was purified rom insect cells (data not shown). 
Therefore, cell extract of Herc5-transfected 293T cells was used as a source of the E3. 
Cell-extract of non-transfected 293Ts was used as the negative control. As seen in Fig 
3.14, a DTT resistant ISG15 conjugate corresponding to a molecular weight of 85 kDa 
was detected only when wild-type Herc5-transfected ell extract was included in the 
reaction mix. The band was not detected with cell extract of cells transfected with the 
C994A mutant of Herc5 or wild-type Herc6. The same conjugate was also seen when 
extract from IFN-β-treated cells was added to the reaction, further indicating that a bona 
fide substrate was being modified by ISG15 in vitro. I ruled out the possibility that the 
band corresponded to a Herc5 auto-conjugation product because cells transfected with 
different sized tags (TAP and Flag) gave the same conjugate (data not shown). Further 
experiments will be required to determine the identity of the substrate (85 kDa band) that 
is conjugated to ISG15 in vitro. While this is still a crude system, this is the first assay 
system to reveal Herc5-dependent ISG15 conjugation ctivity in vitro.  This represents a 
starting point for further purification of Herc5 and other components required for ISG15 
























































Figure 3.14 In vitro assay for ISG15 conjugation. Ube1L and UbcH8 were 
expressed and purified from insect cells. ISG15 was expressed and purified 
from bacteria and labeled with 32P-γ-ATP prior to use. Exracts of 293T cells 
mock transfected (lane 1) or transfected with plasmid  expressing E6AP (lane 
2), wild type Herc5 (lane 3), the C994A mutant (lane 4) or Herc6 (lane 5) were 
used as a source of E3. Purified E1, E2 and labeled ISG15 were incubated in the 
reaction buffer at room temperature for 30 min, with cell extract. Reactions 
were stopped by adding 1X SDS-PAGE loading buffer without DTT. The p85 
conjugate and the Ube1L~ISG15 thioester are indicated. 
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3.3 Discussion   
The results presented here show that the Herc5 HECT E3 enzyme is required for 
conjugation of ISG15 to a broad range, and potentially he complete range, of natural 
ISG15 target proteins. The coordinate induction of ISG15, Ube1L, UbcH8, and Herc5 by 
IFN-β is also consistent with a central role for Herc5 in the conjugation system. The most 
straightforward model for the involvement of Herc5 in the ISG15 system is that it 
participates directly as an ISG15 ligase, as part of an ISG15 transthiolation cascade from 
Ube1L to UbcH8 to Herc5, with Herc5 catalyzing ISG15-target protein conjugation. This 
model is supported by our proteomic analysis of ISG15-conjugated proteins, where 
Ube1L, UbcH8, and Herc5 were all identified as ISG15-conjugated proteins (197). In 
addition, a HECT E3 enzyme that can interact with UbcH8 (Saccharomyces cerevisiae 
Rsp5) was shown to form an ISG15 thioester intermediat  and catalyze ISG15 
conjugation in vitro (196). This indicates that there are no inherent structural 
impediments that prevent a HECT E3s from catalyzing ISG15 conjugation.  
One approach to prove that Herc5 participates directly as an ISG15 ligase would 
be to establish an i  vitro system in which Herc5 forms an ISG15 thioester and 
conjugates ISG15 to a natural ISG15 target protein. However, I have not yet succeeded in 
preparing purified recombinant Herc5 protein or protein fragments (e.g. the HECT 
domain alone) that can be activated with either ubiq itin or ISG15 in vitro. Hence, 
mammalian cell extract containing active Herc5 was used as a source of E3s. Although a 
thioester bond between Herc5 and ISG15 has so far not been detected, I have 
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demonstrated a direct correlation between active Herc5 and an 85 kDa conjugate seen in 
in vitro assays. Future experiments in the lab will focus on further refining this assay 
system and determining the identity of the 85 kDa conjugate. Also, other mutants of 
Herc5 will be expressed and purified from insect cells with the hope that some of these 
might be active in an in vitro assay. 
Alternative models for the role of Herc5 in ISG15 conjugation cannot be ruled 
out. For example, it is conceivable that Herc5 might catalyze a ubiquitination event that is 
a prerequisite for ISG15 conjugation. However, siRNA-mediated depletion of the E1Ub 
enzyme did not result in any decrease in Herc5-dependent ISG15 conjugation activity in 
non-IFN-treated cells (data not shown). In addition, Herc5 is more likely to have a direct 
role in ISG15 conjugation because it was auto-conjugated to ISG15 in vivo. A 
proteomics-based approach identified 158 ISG15 targe  proteins at a very high 
confidence level (197). If Herc5 acts directly as an ISG15 E3 enzyme, this would imply 
that this single E3 has the capacity to recognize, either directly or indirectly, a large 
number of target proteins. SUMO conjugation utilizes a relatively small number of E3s, 
however, Ubc9, the SUMO conjugating enzyme, is distinct from other conjugating 
enzymes in that it mediates substrate interaction. Most substrates are sumoylated on a 
conserved ΨKXD/E motif (where Ψ is a bulky aliphatic group and X is any amino acid), 
which is recognized by Ubc9 (155). Analysis of target proteins identified to date has not 
revealed a motif common to target proteins that might be directly recognized by Herc5. 
An alternative is that additional cellular proteins or factors might mediate the interaction 
of Herc5 with individual target proteins or subsets of target proteins. Our previous 
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demonstration that at least some HECT E3s have the capacity to catalyze ISG15 
conjugation in vitro (196) raises the question of what might limit the participation of 
HECT E3s other than Herc5 from participating in the ISG15 conjugation system. The 
involvement of accessory or "licensing" factors might explain how other HECT E3s are 
prevented from catalyzing ISG15 conjugation.  
Of the six human Herc proteins (Herc1–6), Herc6 is the most similar to Herc5 (48 
% identical), and its expression is also induced by IFN-β. While I did not detect an effect 
of Herc6 siRNAs on overall ISG15 conjugation, it is possible that Herc6 plays a minor 
role in ISG15 conjugation, perhaps targeting a limited set of proteins compared with 
Herc5. Further biochemical comparisons of Herc5 and Herc6 will be important for 
identifying the determinants of Herc5 that confer its dominant function in the ISG15 
system. In chapter 4, I describe the results of Herc5-Herc6 chimeric proteins and also 
show that Herc6 has the capability to function with ISG15. 
In addition to Herc5 and Herc6, our microarray analysis identified several TRIM 
(tripartite motif) proteins that were induced by IFN-β, some of which have been shown to 
function as ubiquitin E3s (122) and at least one of which (TRIM25/Efp) has been 
reported to interact with UbcH8 (175). siRNAs that targeted TRIM25/Efp had no effect 
on the overall pattern or accumulation of ISG15 conjugates nor did transfection of 
TRIM25 expression vectors boost or alter the overall pattern of ISG15 conjugates. A 
recent report showed that Efp could auto-conjugate ISG15, however, the levels of 
ubiquitin-conjugated Efp were much higher than thatof ISG15 conjugated Efp (134), 
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indicating that it functions more efficiently with ubiquitin. Another report stated that 
Efp/TRIM25 could conjugate ISG15 to 14-3-3σ (200). Efp is a well characterized 
ubiquitin ligase implicated in breast cancer because it targets 14-3-3σ, a negative 
regulator of cell cycle, for proteolytic degradation. The finding that it also conjugates 
ISG15 to the same substrate 14-3-3σ, could be because in interferon-treated cells, the 
high levels of UbcH8, ISG15 and Efp/TRIM25, might force the ligase to react with 
ISG15, albeit less efficiently. The authors propose that in the absence of interferon-
induced Ube1L, UbcH8 and ISG15, Efp/TRIM25 functions as a ubiquitin ligase, but it 
might perform a dual role of a ubquitin/ISG15 ligase in the presence of ISG15 
conjugating enzymes. Recently, Gack et al showed that Efp/TRIM25 was essential for 
RIG-I mediated anti-viral activity (35). Efp/TRIM25 mediates robust ubiquitination of 
the caspase recruitment domains (CARDS) of RIG-I, which enhances RIG-I downstream 
signaling. This role of Efp/TRIM25 might explain why a ubiquitin ligase is upregulated 
in the presence of interferons.  
The demonstration that Herc5 is required for ISG15 conjugation to a broad 
spectrum of target proteins in human cells will facilitate analysis of effects of ISG15 
conjugation on target proteins and elucidation of the role of ISG15 conjugation in anti-
viral and anti-microbial responses. In chapter 5, I will describe the identification of an 
additional cellular protein that is required for Herc5-dependent ISG15 conjugation.   
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CHAPTER 4: ANALYSIS OF HERC5 MUTANTS AND HERC5-
HERC6 CHIMERAS  
4.1 Introduction 
Herc5 belongs to the HECT and RCC1-like domain (HERC) family of proteins. 
In humans, this family is characterized by six membrs, Herc1-6, all of which have one 
or more RCC1 (Regulator of chromosome condensation)-like domains (RLDs) at the N-
terminus and a HECT domain at the C-terminus (59). The HERC family is distinctly 
divided into large and small members. Herc1 and Herc2, which are about 500 kDa, 
belong to the former category whereas Herc3-6 are about 120 kDa and are part of the 
latter group. 
Herc5 contains one RLD from residues 157 through 377, which is composed of 
four RCC1-like repeats of approximately 50 amino acids each. These repeats were first 
discovered in the RCC1 protein, which functions as a guanine nucleotide exchange factor 
(GEF) for the small G-protein Ran. RCC1 consists solely of seven tandem repeats, which 
form a seven-bladed β-propeller structure, one face of which interacts with Ran (154) and 
the other side binds chromatin histones H2A and/or H2B (136). The RLDs of Herc1 and 
RPGR (Retinitis Pigmentosa GTPase Regulator) functio  as protein interaction domains, 
binding clathrin heavy chain and PDE-δ (cyclic GMP phosphor-diesterase delta subunit), 
respectively (109, 157). The function of the RLDs of other Herc proteins is not known, 
but it is generally thought that they are protein-protein interaction motifs that might be 
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important for recruiting substrates and/or regulation of the catalytic activity of Herc 
proteins. Mutants of Herc5 were made to test the importance of the RCC1-like repeats for 
Herc5 activity.  
Herc5 has a HECT domain spanning the last 350 amino acids of the protein. Prior 
to the finding described in the previous chapter, HECT domain proteins were thought to 
mediate only ubiquitin conjugation. Herc5 is the first example of a HECT E3 that 
catalyzes the transfer of a Ubl. A mutation of the active site cysteine resulted in an 
inactive enzyme, implying that Herc5 catalyzes ISG15 conjugation via an ISG15 
thioester intermediate (18). As mentioned in Chapter 1, a highly conserved phenylalanine 
usually at the fourth to last position from the C-terminus of HECT domains (-4F) was 
shown to be important for transferring ubiquitin to the substrate without affecting thio-
ester bond formation (161). It was proposed that the -4F might be important for correctly 
orienting the ubiquitin while it is tethered via a thioester bond to the active site cysteine, 
allowing the substrate lysine to attack. In Herc5, this phenylalanine is at the second to last 
position (-2F) and analysis of a mutant at this position will be described below.   
Pfam analysis revealed that in addition to the RLD and HECT domains, the 
central region of Herc5 (residues 554 and 579) harbors a domain with weak similarity to 
a Death Domain (DD). Death domains were first identified in tumor necrosis factor 
receptor (TNFR1) and FAS (172), where they cause aggregation of their respective 
receptors through homotypic interactions. Initially, death domain bearing proteins were 
thought to be involved in apoptotic pathways only. Subsequently, these domains have 
been discovered in other signaling molecules also and are considered to be protein 
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interaction motifs. Given the low similarity to characterized DDs, it is unlikely that this 
domain operates as a true DD. However, we were intrigued by the position of this domain 
within Herc5, which corresponds closely to substrate binding domains in some other 
HECT E3s. For example, the E6-binding site of E6AP is centered approximately 100 
residues upstream of the HECT domain, spanning 17 amino acids (72). The third WW 
domain of Rsp5, which is required for binding to several substrates, is also centered 
approximately 100 amino acids upstream of the HECT domain (30, 64) (See Fig 4.1). 
The death-like domain is similarly positioned, approximately 100 residues upstream of 
the Herc5 HECT domain, and could potentially be involved in mediating substrate 
recognition. In light of the previous results with HECT proteins, we will refer to this 25 
amino acid region as the putative substrate binding box (SBB). The effects of deletions 
within this region will be describe 
Among the HERC family members, Herc6 is most closely r lated to Herc5, with 
the two proteins sharing 48 % overall identity, and 66% identity within the HECT 
domain. Herc6 has five RCC1-like repeats that extend from residues 42 to 305, as 
compared to the four RCC1-like repeats found in Herc5 (Fig 4.2). Sequence analysis of 
Herc6 did not show any conserved motifs in the region corresponding to the substrate 
binding box (SBB) of other HECT proteins, but secondary structure prediction revealed 
that both Herc5 and Herc6 share a similar structure throughout the length of the protein, 
including the SBB. Further, the Herc6 gene, like Herc5, is also transcriptionally induced 
by interferons α and β (18). Although my previous data from human cell lines indicates 
that Herc6 is not a major ligase for ISG15, I tested whether it is conjugated to ISG15. I 
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show here that Herc6 is a substrate for Herc5-dependent ISG15 conjugation, and it also 
exhibits auto-conjugation of ISG15. Further, chimeras were made between Herc5 and 




Figure 4.1 A schematic showing the substrate binding box (SBB). The schematic 
shows E6AP, Rsp5 and Herc5 and their respective domains. The SBB is positioned 
approximately 100 amino acids upstream of the HECT domain and is marked by a 
dotted rectangle in the figure. It corresponds to the E6-binding region of E6AP and the 
3rd WW-domain of Rsp5 that binds to at least a subset of targets. This might also be 





















Figure 4.2 A schematic comparing Her4, Herc5 and Herc6. The RCC1-
like domains (RLD) and the HECT domains of the Herc proteins are shown 
in green and maroon, respectively. Each RCC1-like rep at is represented 
by one square. Herc5 has a putative fifth RCC1-like repeat, indicated by 
the striped green square. In addition to sharing close sequence similarity 
with Herc5, the secondary structure of Herc6 is also predicted to be similar 
to that of Herc5.  Like Ube1L, UbcH8, Herc5 and ISG15, the gene for 













Analysis of ∆F mutant of Herc5 
While HECT domains have been well characterized with respect to ubiquitin 
catalysis, Herc5 is the first example of a HECT domain protein involved in Ubl 
conjugation. To determine whether the conserved phenylalanine residue, which is at the 
second to last position in Herc5 (-2F), affects transfer of ISG15 to substrates, the last two 
amino acids of Herc5 were deleted to create the ∆F mutant. This mutant was tested in 
HeLa cell transfections for its ability to support ISG15 conjugation. It was shown 
previously that non-interferon-treated cells transfected with plasmids expressing ISG15, 
Ube1L, and UbcH8 showed a low level of ISG15 conjugation which increased 
dramatically when wild type Herc5 was included in the ransfection. In contrast, the 
catalytically inactive C994A mutant did not increas the conjugates beyond the basal 
level. This assay was used to test the ∆F mutant. Figure 4.3 shows a higher level of 
ISG15 conjugates accumulated when cells were transfected with wild type Herc5 (lane 2) 
as compared to cells with no transfected Herc5 (lane 1) or the C994A mutant (lane 3). 
When cells were transfected with the ∆F Herc5 mutant along with E1, E2 and ISG15, 
there was no boost in ISG15 conjugates (lane 4), indicating that the ∆F mutant could not 
conjugate substrates. Auto-conjugation is a property of some ubiquitin ligases and I had 
previously shown that Herc5 could ligate ISG15 to itself. TAP-tagged Herc5 was 
transfected with the ISG15 conjugation machinery, and extracts were probed with anti-
TAP antibody to detect auto-conjugation. Wild type H rc5 showed strong auto-
conjugation, as detected from the smear of high molecular weight conjugates, whereas 
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the C994A mutant was completely inactive and showed no conjugates (Fig 4.2 lanes 5 
and 6). In comparison, the ∆F mutant showed very few conjugates and a large proporti n 
of the protein was not modified, clearly indicating that this mutant was defective in auto-
conjugation (Fig 4.2 lane 7). Similar results were obtained with the -4F mutants of E6AP 
and Rsp5, which were defective in transferring ubiqit n onto substrates (161). While it is 
not known whether ∆F is capable of forming a thioester bond with ISG15, based on the 
results of analogous -4F mutants in other HECT E3s it is expected that the thioester bond 



















Figure 4.3 The ∆F mutant, similar to -4F mutants of ubiquitin ligases, is 
defective in auto-conjugation. HeLa cells were transfected with Ube1L, UbcH8 
and FLAG-ISG15, with no Herc5 (lane 1), with wild type Herc5 (lanes 2 and 5), 
with C994A mutant (lanes 3 and 6) or with the ∆F mutant. Cell extracts were 
immunoblotted with Anti-FLAG antibody (left panel) or with anti-TAP antibody 
(right panel).  
Herc5: - WT C-A ∆F WT C-A ∆F
1          2          3            4                5         6                7




Analysis of RLD and SBB mutants 
As mentioned above, Herc5 has four RCC1-like repeats spanning residues 157 to 
377, which are postulated to be protein interaction motifs. To assess the importance of 
these repeats in ISG15 conjugation, a set of truncations were made (Fig 4.4). Substrate 
conjugation as well as auto conjugation activities of each mutant were tested in HeLa cell 
transfections. The ∆RCC construct, spanning residues 381-1024, lacked the RCC1-like 
repeats. This mutant was unable to conjugate ISG15 to substrates, but it retained auto-
conjugation activity (Fig 4.5). This suggests that the RCC1-like domains are involved in 
substrate recognition. It is interesting to note that t e auto-conjugation pattern of this 
mutant was different from that of the wild type protein. While the wild type protein 
showed distinct ISG15 conjugates, the ∆RCC mutant showed a smear of very high 
molecular weight conjugates (Fig 4.5 compare lanes 7 and 9). Also, a bigger fraction of 
the protein pool was conjugated in the ∆RCC mutant compared to the wild type protein.  
Figure 4.4 Schematic showing the RLD mutants and the SBB mutant. The 
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Figure 4.5 Auto-conjugation and substrate conjugation activities of the 
RLD-mutants. HeLa cells were transfected with Ube1L, UbcH8 and FLAG-
ISG15 with no Herc5 (lane 1) or wild type Herc5 (lane 2 and 7) or with 
Herc5 mutants as indicated. Cell extracts were analyzed by immunoblotting 
with anti-FLAG antibody (left panel) or anti-TAP antibody (right panel).  
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An N-terminal truncation deleting the first 156 residues of the protein (∆150) 
retained all the RCC1-like repeats and it was analyzed for both substrate modification as 
well as auto-conjugation. The auto-conjugation activity of this mutant was intact, and it 
resembled the ∆RCC mutant in that a major portion of the protein was conjugated to 
ISG15 (Fig 4.5 lane 10). However, this mutant did not i crease the levels of ISG15 
conjugates when co-transfected into cells with E1, E2 and ISG15, indicating that it was 
unable to modify substrates (Fig 4.5 lane 5). This implies that the first 150 amino acids of 
the protein are important for substrate conjugation. However, there is a fifth RCC1 repeat 
with a low match score (Pfam) between residues 130 and 153, which might be 
contributing to substrate conjugation. The first 100 amino acids of Herc5 were deleted 
(the ∆100 mutant), leaving this additional putative RCC1 repeat intact. As with the 
previous two N-terminal truncations, this mutant also displayed efficient auto-
conjugation but no substrate conjugation (Fig 4.5 lanes 6 and 11). This clearly indicates 
that the first 100 amino acids of Herc5 are required for substrate conjugation. Although 
no recognizable domains are present in this stretch of t e protein, it is possible that the 
region up to the first 100 amino acids might contain determinants important for substrate 
conjugation. Alternatively, it is possible that the N-terminus of the protein is needed for 
proper folding of the RCC1-like repeats, which are responsible for mediating substrate 
interaction. Future work in the lab will test these various hypotheses. 
To determine the importance of the substrate binding box (SBB) for Herc5-
mediated ISG15 conjugation, a mutant protein lacking this domain (amino acids 554-579) 
was constructed (∆SBB). This mutant did not conjugate ISG15 to substrates, implying 
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that the SBB is important for mediating interactions with substrates, either directly or via 
other factors or adaptors that recruit substrates. Like the N-terminal mutants described 
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Figure 4.6 Auto-conjugation and substrate conjugation activities of ∆SBB mutant. 
HeLa cells were transfected with plasmids expressing Ube1L, UbcH8 and ISG15, 
with no Herc5 (lane 1) or wild type Herc5 (lanes 2 and 5) or the C994A mutant 
(lanes 3 and 6) or the ∆SBB mutant (lanes 4 and 7). Cell extracts were  
transferred onto a nitrocellulose membrane and probed with anti-FLAG antibody 
(left panel) or Anti-TAP antibody (right panel). 
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Herc6 is conjugated to ISG15 
As mentioned in the introduction, among the HERC memb rs, Herc6 is most 
closely related to Herc5 (48% overall identity) and the two proteins share similarities in 
sequence and secondary structure predictions. Further, like Herc5 and the other enzymes 
of the ISG15 pathway, Herc6 expression is induced by IFN-β (18) suggesting that Herc6 
might be a part of the conjugation machinery. My earli r results with siRNAs showed 
that knocking down Herc6 did not have an effect on ISG15 conjugation in interferon-
treated cells (18). Similarly, transfecting Herc6 plasmid did not boost conjugates in non-
interferon-treated cells co-transfected with Ube1L, UbcH8 and ISG15. These results 
indicated that Herc6 does not play a major role in ISG15 conjugation, however we could 
not rule out that Herc6 might play a minor role, perhaps by targeting a small number of 
specific substrates.  
An alternative assay for whether Herc6 might be involved in ISG15 conjugation 
was to determine whether Herc6 catalyzed auto-conjugation to ISG15. HeLa cells were 
transfected with Ube1L, UbcH8, ISG15 and TAP-tagged H rc6, and an immunoblot was 
probed with anti-TAP antibody to detect Herc6. Figure 4.7A shows high molecular 
weight conjugates of Herc6 only in presence of Ube1L, UbcH8, and ISG15. No 
conjugates were detected when either UbcH8 or ISG15 were omitted from the 
transfection mix. To determine whether these ISG15 conjugates were a result of Herc6 
auto-conjugation, the catalytic cysteine residue at position 985 was mutated. When the 
C985A mutant was transfected into cells along with the E1, E2 and ISG15, conjugation 
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was decreased but not eliminated (Fig 4.7 B, compare lanes 1 and 3), indicating that at 
least some of the Herc6 conjugates were not a result of auto-conjugation.   


















Figure 4.7 Herc6 is conjugated to ISG15 in the presence of Ube1L and UbcH8. A) HeLa 
cells were co-transfected with TAP-Herc6 plasmid anvarious combinations of plasmids 
expressing Ube1L, UbcH8 and ISG15. Cell extracts were analyzed by immunoblotting 
with anti-TAP antibody. B) Ube1L, ISG15 and Herc6 (wild type or the C985A mutant) 
were co-transfected with (lanes 1 and 3) or without (lanes 2 and 4) UbcH8. Cell extracts 
were analyzed by immunoblotting with anti-TAP antibody. 
A. 
B. 
UbcH8: +          - +         -
Herc6 WT Herc6 C-A







I had previously shown that there is a basal level of Herc5 in non-IFN-treated 
cells, which is responsible for the ISG15 conjugates that accumulate in a triple 
transfection of plasmids expressing Ube1L, UbcH8 and ISG15 (18). To determine 
whether Herc6 conjugation was Herc5-dependent, cells were first treated with siRNAs to 
knock-down Herc5 and then co-transfected with Ube1L, UbcH8 and ISG15 and TAP-
tagged Herc6. Figure 4.8 shows that in the case of Herc6 C985A mutant, knocking down 
Herc5 abolished all ISG15 conjugates (lane 4), indicating that the C985A mutant was 
conjugated by Herc5. On the other hand, wild type Herc6 retained some conjugates even 
when Herc5 was knocked down (Fig 4.8 lane 2). Since this conjugation is not dependent 
on Herc5 and is dependent on the catalytic activity of Herc6, it is likely the result of 
ISG15 auto-conjugation activity of Herc6.  
siRNA:     - H5 - H5
Herc6 WT Herc6 C-A





Figure 4.8 Herc6-ISG15 
conjugation is a combination of 
auto-conjugation and Herc5-
dependent conjugation. HeLa cells 
were mock-transfected (lanes 1 and 
3) or transfected with siRNAs 
against Herc5 (lanes 2 and 4) and 
subsequently transfected with 
plasmids expressing Ube1L, 
UbcH8, ISG15 and wild type Herc6 
or the C985A  mutant. Cell 




To further investigate the significance of Herc5 and Herc6 auto-conjugation, I 
determined whether another HERC protein, Herc4, has ISG15 auto-conjugation activity. 
Herc4 is 34% identical to Herc5 and phylogenetic analyses indicate that Herc4 is likely to 
be the common ancestor of all HERC proteins (59). Herc4 has four RCC1-like repeats, 
spanning residues 7 to 230, and unlike Herc5, Herc4 does not have a significant leader 
sequence preceding the RLD (Fig 4.2). There is no ident fiable motif present in the region 
corresponding to the Herc5 SBB and secondary structure prediction (network protein 
sequence analysis – NPSA) indicates that Herc4 is significantly different from Herc5 
over this stretch. Also, as our microarray results indicate, the gene for Herc4 is not 
upregulated by IFN-β. Figure 4.9 shows that TAP-Herc4 was not conjugated to ISG15 
under the same conditions where TAP-Herc5 and TAP-Herc6 were both efficiently 
modified.  As an additional negative control, TAP-E6AP also did not auto-conjugate 
ISG15 (data not shown), strongly suggesting that the ability to function with ISG15 in 





















Figure 4.9 The ability to function with ISG15 is limited to Herc5 and Herc6. 
HeLa cells were transfected with plasmids expressing Ube1L, UbcH8, ISG15 
and TAP-Herc5 (lane 2) or TAP-Herc6 (lane 4) or TAP-Herc4 (lane 6). As a 
control, each of the Herc proteins were also transfected without UbcH8 
expressing plasmids (lanes 1, 3 and 5). Cell extracts were transferred to a 
nitro-cellulose membrane and probed with anti-TAP antibody. 
UbcH8: - +         - +          - + 
Herc5 Herc6 Herc4









In spite of the similarities between Herc5 and Herc6, Herc5 is the only E3 that has 
been found to have a broad effect on ISG15 conjugation to substrate proteins. To 
investigate whether this disparity mapped to the HECT domain or the region upstream of 
the HECT domain, chimeric proteins were expressed where the HECT domains of the 
two proteins were switched (Fig 4.10). The chimera with the N-terminus of Herc5 and 
HECT domain from Herc6 was referred to as Herc 5/6 and the converse chimera was 
labeled Herc 6/5. Both the chimeric proteins were transfected into non-interferon-treated 
HeLa cells to check whether they could catalyze auto-conjugation and enhance 
conjugation to substrates. Neither chimera increased th  level of ISG15 conjugates over 
that seen in the absence of any Herc5 protein (Fig 4.11 A), indicating that the HECT 
domain of Herc6 cannot substitute for the Herc5 HECT domain. This could be because 
the Herc6 HECT does not function as efficiently with UbcH8 and/or ISG15, as suggested 
from the respective auto-conjugation activities of Herc5 and Herc6 (Fig 4.9). It is also 
clear that other determinants within Herc5 (e.g. RLDs or SBB) are important for substrate 
conjugation, since the Herc5 HECT domain was not sufficient to convert Herc6 into a 
major ISG15 ligase. It should be mentioned here that we have had little success in our lab 
getting active chimeras by exchanging HECT domains of various proteins (e.g. Rsp5 and 
E6AP). This suggests that there may be interactions between the N- and C-terminal 
regions of HECT E3s and switching one HECT domain for another might disrupt their 
function.  Both the chimeras displayed auto-conjugation activity, however, there was a 
difference in their patterns of auto-conjugation (Fig 4.11 B). Chimera Herc6/5 was 
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modified similar to the ∆RCC mutant, with very high molecular weight conjugates at the 
top of the gel  (Fig 4.11 B compare lane 3 with lanes 4 and 5). One possible model that 
could explain this difference is that the N-terminal region of Herc5 has an inhibitory 
effect on protein activity and any mutants that delete/replace this region display an 


















Figure 4.10 Schematic showing Herc5-Herc6 chimeras. The Herc5 and Herc6 
proteins are shown in black and blue, respectively. Herc 5/6 retains the N-
terminus of Herc5 while the HECT domain belongs to Herc6. Herc 6/5 is the 







































































































































































Figure 4.11 Substrate conjugation and auto-conjugation activities of Herc5-Herc6 
chimeras. HeLa cells were transfected with plasmids expressing Ube1L, UbcH8, ISG15 
and different Herc5 constructs, as indicated. Cell extracts were prepared and analyzed by 
immunoblotting with A) anti-FLAG antibody to detect ISG15 conjugates and B) anti-TAP 




While the HECT domains of Herc5 and Herc6 represent the most conserved 
region of the two proteins, they differ in the position of the conserved phenylalanine 
residue found at the fourth position from the carboxyl terminus of most HECT E3s (-4F). 
This residue was previously shown to play a role in promoting ubiquitin conjugation 
(161). In Herc5, this phenylalanine is at the second from last position (-2F), while in 
Herc6 it is at the ninth from last position (-9F). We tested whether this difference might 
be related to the ability of Herc5 to function in the ISG15 pathway by replacing the last 
residue of Herc5 (FG) with the last eight residues of Herc6 (FVSPMLTGS). Fig 4.12 
shows that this mutant (C5–6) stimulated ISG15 conjugation as efficiently as wild-type 
Herc5. The divergent carboxyl-terminal tails are threfore not the basis for the functional 




















Figure 4.12 Auto-conjugation and substrate conjugation activities of the C5-6 
chimera. HeLa cells were transfected with Ube1L, UbcH8 and FLAG-ISG15, 
with no Herc5 (lane 1), with wild type Herc5 (lanes 2 and 5), with the C994A 
mutant (lanes 3 and 6) or with the C5-6 chimera. Cell extracts were 
immunoblotted with Anti-FLAG antibody (left panel) or with anti-TAP 
antibody (right panel). The box shows the sequence of the C-terminal residues 
of Herc5 and Herc6. The residues following the Phe were switched between 
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A set of point mutations and deletions were made to investigate the role of each of 
the Herc5 domains: RCC1-like repeats, the putative substrate binding box (SSB) and the 
HECT domain. While it is known that the HECT domain is responsible for the catalytic 
activity of the protein, this is the first example of a HECT domain involved in non-
ubiquitin catalysis and it was not known whether the mechanisms would be conserved. 
The residues that are important for ubiquitin thioester bond formation (catalytic cysteine) 
and for transfer of ubiquitin to substrates (-2F) were shown here to be important for 
ISG15 catalysis, suggesting that ISG15 conjugation employs a similar mechanism. 
Currently, the in vitro thioester assay does not work with Herc5, but our work with other 
HECT E3s has shown that this phenylalanine residue does not interfere with thio-ester 
bond formation.  
The role of RCC1-like repeats was analyzed by making a set of N-terminal 
truncations. So far, it is not clear whether the RCC repeats are important for ISG15 
conjugation to substrates, but a region N-terminus to the RCC1-like repeats was required 
for conjugating ISG15 to substrates. An inspection of the residues upstream of the RCC1-
like repeats did not show any known motifs. While it is possible that these residues form 
a hitherto unknown motif important for binding proteins, it could also be that this region 
is required for the correct folding of the RCC1-like repeats. In other proteins RLDs are 
known to represent protein-protein interaction motifs (109, 157) and here, too, they 
maybe required for recruiting substrates and/or adaptor protein(s). The following chapter 
will describe the identification of one such adaptor protein. 
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Interestingly, N-terminal truncations and the ∆SBB mutant were auto-conjugated 
more robustly than wild type Herc5 (Fig 4.5 and 4.6). While only a relatively small 
fraction of Herc5 was auto-conjugated to ISG15 in the presence of the E1, E2 and E3, 
almost the entire pool of the ∆RCC1 and ∆SBB proteins were modified under the same 
conditions. A similar increase in activity was seen in the Herc6/5 chimera, where the N-
terminus of Herc5 had been replaced by the N-terminus of Herc6. One model to account 
for these observations is the Herc5 normally exists in a closed and catalytically inactive 
conformation, possibly mediated by interactions betwe n the RLD and the SSB domains.  
Deletion of either of these domains results in a constitutively activated enzyme (hence the 
robust auto-conjugation activity), however the fact that normal substrates are not 
recognized by either the ∆RCC1 or ∆SBB mutants indicates that both regions are critical 
for interacting with substrates and/or adaptor proteins.    
The induction of Herc6 by interferon and its similarity to Herc5 made it a likely 
candidate for a ligase of ISG15. Even though our earlier studies showed that knocking 
down Herc6 did not have an obvious effect on overall substrate conjugation (18), we had 
postulated that Herc6 might be a minor ligase for this pathway. The results presented here 
show that Herc6 is a substrate of Herc5-mediated ISG15 conjugation and it could also 
auto-conjugate ISG15, though not as robustly as Herc5. Both Herc5 and Herc6 are 
located on chromosome 4, and Herc5 was proposed to have been derived from Herc6 via 
gene duplication (59). Rodents (rats, mice) have a homolog for Herc6 but not a Herc5 
homolog. This raises the question of how mice conjugate ISG15 to substrates (42). Also, 
it is not clear whether the gene duplication event did not occur in rodents or whether they 
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lost the Herc5 gene during evolution. The latter is a more likely possibility, since the 
genomes of other mammals (dog, cow) retain a Herc5-ncoding gene and suggest that the 
gene duplication event giving rise to Herc5 occurred b fore these families split from a 
common ancestor. It has been reported that mice hava gene for Ube1L and UbcM8, 
both of which are similar to their human homologs (96). I showed that Herc6 can 
function with Ube1L and UbcH8 to auto-conjugate ISG15. In light of the above results, it 
is conceivable that Herc6 plays a major role in ISG15 conjugation in rodents.   
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The identification of Herc5 as the major E3 for ISG15 raised several important 
questions. First, how is it possible for a single enzyme to recognize such a diverse 
spectrum of substrates? There may be consensus sites on substrates that are targeted by 
the E3, however, there have been no obvious motifs by sequence comparison. 
Alternatively, there might be accessory factor(s) that bind Herc5 and mediate its 
interaction with target proteins. Second, what prevents other HECT E3s such as E6AP, 
which are capable of interacting with UbcH8 and forming a thioester bond with ISG15 in 
vitro, from functioning with ISG15 in vivo? This could be explained if a protein was 
exclusively binding enzymes of the ISG15 pathway, thus channeling their activities and 
also preventing proteins of the ubiquitin system from impinging. Such proteins, called 
scaffolding proteins, are known to exist for other signaling pathways such as the MAP 
kinase pathway. There is considerable diversity in the MAP kinase pathway, not just with 
regard to stimuli, but also downstream targets. In S. cerevisiae there are as many as six 
MAP kinase cascades that respond to various external stimuli. The complexity of this 
pathway is further increased by the fact that some components are very similar and some 
of these kinases can function in more than one cascade. In order to ensure the correct 
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response to a particular stimulus, the proper kinase must be activated and it must 
phosphorylate the right targets. This specificity is maintained, at least in part, by scaffold 
proteins that mediate kinase-kinase interactions or kinase-substrate interactions. The SH2 
and SH3 domain containing proteins are adaptors that connect receptor tyrosine kinases 
to their downstream targets like Ras (143). Accessory proteins can co-ordinate protein 
complexes and channel the signal into a particular cascade. The S. cerevisiae protein Ste5 
was shown to interact with Ste11 (a MEK kinase - MEKK), Ste7 (a MAP or ERK kinase 
- MEK) and Fus3 (a mitogen activated protein kinase - MAPK) in the mating pathway 
(25). In some cases, scaffold proteins have also been shown to activate their binding 
partners. For example, the MEK kinase 1 (MEKK1) hasa large N-terminal domain that 
interacts with different components of the JNK module and its kinase domain activates 
the JNK (c-Jun N-terminal kinase) pathway (129).  
Drawing parallels with the MAPK pathway, an accessory protein that insulates 
the ISG15-specific proteins from the ubiquitin enzymes and/or co-ordinates Herc5 
activity and its interaction with substrates would explain the questions raised above with 
regards to the role of Herc5. In a proteomics study to determine the substrates of ISG15 
conjugation, IQGAP1, a scaffold protein, was identified as one of the high-confidence 
targets, with eleven peptides of this protein identified by mass-spectrometry (197). In 
previous such analyses with ubiquitin and SUMO (21,145), enzymes that function in the 
Ubl pathway were found to be modified by the Ubl and similarly, Ube1L, UbcH8 and 
Herc5 were all conjugated to ISG15 (197). I hypothesiz d that IQGAP1 might be 
involved in the ISG15 pathway as a substrate-recruiting adaptor protein due to its multi-
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domain nature (described below), and that its conjugation to ISG15 might be a reflection 
of its involvement in the conjugation system. Furthe , it might function as a scaffold that 
interacts exclusively with enzymes of the ISG15 pathw y, thus preventing ubiquitin E2s 
and E3 from being mis-charged with ISG15.  
IQGAP1 is a 189 kDa modular protein, which is involved in various pathways 
related to cell motility and cell-cell adhesion (12). There are several domains throughout 
the length of this protein (Fig 5.1), including a calponin-homology domain (CHD) at its 
N-terminus, a coiled coil region, four tandem IQ repeats, a WW domain and at its C-
terminus, there is a Ras-GAP-related domain (GRD). It has been shown to interact with 
several cellular proteins, including several simultaneously. Complexes of IQGAP1 with 
Cdc42 and actin (27), with Rac1/Cdc42 and CLIP-170 (34) and with calmodulin and 
Cdc42 (58) have been isolated, implying that IQGAP1 might be functioning as a scaffold 
protein within a cell. IQGAP1 was also shown to interact with members of the MAP-
kinase pathway, specifically extracellular signal-regulated kinase 2 (ERK2) and its 
upstream kinases MEK1, MEK2 and B-Raf (153, 158, 159). Raising or lowering the 
levels of IQGAP1 inhibited epidermal growth factor (EGF) mediated activation of MEK 
and ERK. EGF-mediated activation of B-Raf was absent in IQGAP1-null cells and 
binding to IQGAP1 stimulated the activity of B-Raf in vitro (153). It was concluded that 
IQGAP1 functions as a scaffold for the MAP kinase pathway, increasing the local 
concentrations of enzymes within the pathway, thus bringing selectivity and specificity to 
this complex MAP-kinase pathway.  
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Here I confirm that IQGAP1 is indeed modified by ISG15, as predicted from the 
proteomics study. siRNAs targeting IQGAP1 decreased ISG15 conjugation in IFN-β-
treated cells as well as in cells transfected with Ube1L, UbcH8, ISG15 and Herc5. 
Binding studies showed that IQGAP1 interacts with Herc5 in vitro as well as in vivo, via 
the C-terminus of IQGAP1 and the amino-terminus of Herc5. Auto-conjugation of wild 
type Herc5, but not the ∆RCC1 or ∆SBB mutants, was lost when IQGAP1 was depleted. 
Together, these results indicate that IQGAP1 is an important player in the ISG15 
conjugation pathway and suggest a model wherein IQGAP1 is required, at least in part, 
for Herc5 activity.  
 
 
CHD Coiled-coil WW IQ GRD RGCT
Figure 5.1 A schematic showing the domain architecture of IQGAP1.  
Abbreviations: CHD - calponin homology domain; WW - a WW domain with two 
conserved Trp residues; IQ - IQ motif that binds calmodulin; GRD - RasGAP-





IQGAP1 is conjugated to ISG15 in vivo 
 To confirm the result from the proteomics study that ad identified IQGAP1 as a 
substrate of ISG15 conjugation (197), extracts from IFN-β treated cells were 
immunoblotted with anti-IQGAP1 antibody. Non-IFN-β-treated extracts showed a single 
major band of  189 kDa corresponding to endogenous IQGAP1, while extracts from 
IFN-β treated cells had an additional higher molecular weight band corresponding in size 
to a single ISG15 conjugate (Fig 5.2A, compare lanes 1 and 2). There was no difference 
in levels of IQGAP1 protein between the non-interferon treated sample and the 
interferon-treated sample, indicating that IQGAP1 is not induced by interferon. Since a 
majority of ISG15 conjugates are Herc5-dependent, we tested whether conjugation of 
IQGAP1 was also mediated by Herc5. Cells treated with Herc5 siRNAs did not show the 
IQGAP1-ISG15 conjugate (Fig 5.2A, lane3), whereas a control siRNA had no effect (Fig 
5.2A lane 4). To confirm this result in non-IFN-β-treated cells, 293T cells were 
transfected with TAP-tagged IQGAP1 in the presence of plasmids expressing Ube1L, 
UbcH8, ISG15 and Herc5. As seen in figure 5.2B, the conjugated product was seen only 
when all components of the ISG15 conjugating machinery were included in the 

















































Figure 5.2 IQGAP1 is conjugated to ISG15 in vivo. A) HeLa cells were mock-
transfected (lanes 1 and 2) or transfected with an siRNA against Herc5 (lane 3) or a 
control siRNA (lane 4). The cells were then treated with IFN-β for an additional 
48hrs (lanes 2-4). Cell extracts were analyzed by immunoblotting with anti-IQGAP1 
antibody. B) HeLa cells were transfected with plasmids expressing TAP-IQGAP1 
and various combinations of Ube1L, UbcH8, ISG15 and Herc5. Cell extracts were 
immunoblotted with anti-TAP antibody. 
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siRNAs against IQGAP1 inhibit ISG15 conjugation 
To determine whether IQGAP1 plays a role in promoting ISG15 conjugation, 
rather than simply being a substrate of ISG15 conjugation, two sets of siRNAs were 
designed to target IQGAP1 (IQ1A and IQ1B – See Materi ls and Methods). An 
immunoblot using anti-IQGAP1 antibody shows that at a final concentration of 100 nM, 
both sets of IQGAP1 siRNAs efficiently knock down IQGAP1 at the protein level (Fig 
5.3 A), whereas the Herc5 siRNAs and a control siRNA do not affect it. A time-course 
was performed to determine the optimal time period of siRNA treatment. Figure 5.3B 
shows that cells harvested after 72 hours of siRNA treatment have lower levels of 
IQGAP1 as compared to cells that were harvested 24 hrs and 48 hrs after siRNA 
treatment. For all further experiments involving siRNAs, cells were harvested 72 hrs after 














































































































Figure 5.3 siRNAs against IQGAP1 effectively reduce the levels of IQGAP1 
protein. A) HeLa cells were mock-transfected (lanes 1 and 2) or transfected with 
100 nM and 200 nM of various siRNAs as indicated, and then treated with IFN-β 
for 48 hrs. Cell extracts were immunoblotted with anti-IQGAP1 antibody. B) A 
time-course to determine the optimal time period of siRNA treatment. HeLa cells 
were mock transfected or transfected with a control siRNA or two sets of siRNAs 
against IQGAP1. Cells were harvested after 24 hrs, 48 hrs or 72 hrs and extracts 
were immunoblotted with anti-IQGAP1 antibody. 
 
111 
In order to test whether IQGAP1 was involved in ISG15 conjugation, HeLa cells 
were transfected for 24 hrs with siRNAs to knock down IQGAP1 or Herc5 or a control 
gene, followed by IFN-β treatment for an additional 48 hrs. When immunoblots were 
probed with anti-ISG15 antibodies, an induction of high molecular weight ISG15 
conjugates was seen in IFN-β-treated cells (Fig 5.4A lane 2). Cells in which IQGAP1 
was knocked down (Fig 5.4A lanes 3-6), showed a reduc  level of ISG15 conjugation 
compared to cells with no siRNAs (Fig 5.4A lane 2) or the control siRNA (Fig 5.4A lanes 
7 and 8). The levels of ISG15 conjugation in IQGAP1 knock-down cells was higher than 
the cells in which Herc5 had been knocked down (Fig5.4A lanes 9 and 10), and this is 
likely due to the inefficient IQGAP1 knock-down as compared to the Herc5 knock-down 
(compare Fig 5.3A and 3.1B). 
We had previously shown that non-IFN-treated cells transfected with plasmids 
expressing ISG15, Ube1L, and UbcH8 showed a low level of ISG15 conjugation which 
was increased dramatically when Herc5 was included in the transfection (18).  This 
reconstitution of ISG15 conjugation implied that any additional components required for 
ISG15 conjugation must be constitutively expressed. Figure 5.4B shows an accumulation 
of ISG15 conjugates with the triple (Ube1L, UbcH8 and ISG15) and quadruple (Ube1L, 
UbcH8 and ISG15 and Herc5) transfections. In this context, when cells were pre-treated 
with siRNAs against IQGAP1, they showed an overall decrease in ISG15 conjugation 





















Figure 5.4 A siRNAs against IQGAP1 decrease ISG15 conjugation in IFN-treated cells. 
HeLa cells were mock transfected (lanes 1 and 2) ortransfected for 24 hrs with siRNAs 
to knock down IQGAP1  (lanes 3-6) or Herc5 (lanes 9 and 10) or a control gene (lanes 
7 and 8), followed by IFN-β treatment for an additional 48 hrs. Cell extracts were 


































       











5.4 B IQGAP1 is required for ISG15 conjugation in cells transfected 
with E1, E2 and ISG15. HeLa cells were mock transfected or transfected 
with IQGAP1 or control siRNAs. 24 hrs later, they were transfected with 
plasmids expressing Ube1L, UbcH8 and FLAG-ISG15 withou  (lanes 1-
4) or with (lanes 5-8) Herc5. Cell extracts were transferred to a 
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Having seen a global decrease in ISG15 conjugation in the presence of siRNAs 
against IQGAP1, we analyzed two individual ISG15 targets, Moesin and Thioredoxin 
Reductase 1 (TrxR1). The verification of these proteins as substrates of ISG15 
conjugation has been reported previously (197). Moesin acts as an adaptor between 
plasma membrane and cytoskeletal proteins and was recently shown to have anti-
retroviral activity (133). TrxR1 is a cellular enzyme (TrxR2 is its nuclear counterpart) 
that is involved in protecting cells against oxidatve stress and is upregulated in a number 
of human cancers (132). When these substrates were transfected into non-IFN-treated 
HeLa cells in the presence of Ube1L, UbcH8, ISG15 and Herc5, we could detect their 
ISG15 conjugated forms. However, in the presence of siRNAs targeting IQGAP1, we did 
not detect the modified forms of these substrates, indicating that IQGAP1 is required for 



















Figure 5.5 IQGAP1 is required for conjugation of ISG15 to TrxR1 and Moesin. 
HeLa cells were mock-transfected (lane 2) or transfected with IQ A (lane 3) or a 
control siRNA (lane 4). After 24 hrs they were transfected with plasmids 
expressing V5-TrxR1 (upper panel) or V5-Moesin (lower panel), along with 
Ube1L, UbcH8, ISG15 and Herc5. In lane 1 ISG15 was not included in the 
tranfection mix. Cell extracts were immunoblotted with anti-V5 antibody.  
siRNA: - - IQA     con
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IQGAP1 binds Herc5 in vivo and in vitro 
To determine whether IQGAP1 and Herc5 physically interact with each other, 
Herc5 was expressed as an N-terminally TAP-tagged protein in 293T cells and purified 
on IgG-sepharose beads. TAP-Herc4, TAP-Herc6 and TAP-E6AP were similarly 
expressed and purified as controls. IQGAP1 was expressed as a His-tagged protein and 
purified from insect cells (119). The TAP-tagged proteins immobilized on IgG-
sepaharose beads were tested for binding to purified IQGAP1. Herc5, and to a lesser 
extent Herc6, bound to IQGAP1 (Fig 5.6A), whereas Herc4 and E6AP did not show 
binding above background. I also determined whether IQGAP1 acts as a scaffold to 
recruit UbcH8, the component upstream of Herc5 in the ISG15 cascade. TAP-UbcH8 was 
expressed and purified from 293T cells and was tested for interactions with IQGAP1. 
Figure 5.6B shows that UbcH8 did not bind IQGAP1. 
 
 























































Figure 5.6 IQGAP1 binds Herc5 in vitro. A) TAP-tagged Herc4, Herc5, Herc6 and 
E6AP were purified from 293T cells, immobilized on Ig-G-sepharose beads and 
incubated with purified IQGAP1for 2hrs at 4 oC. The beads were subsequently washed, 
resuspended in 1X loading buffer and loaded on an SDS-PAGE. The gel was 
transferred to a nitrocellulose membrane and bound IQGAP1 was detected by western 
blotting. Lane 1 shows the input, which is 1/5 the amount used in the assays. Lane 2 
indicates the amount of IQGAP1 bound to IgG sepharose beads only and is considered 
the background. The lower panel shows the TAP-tagged proteins. B) Same as A, 
except, TAP-tagged UbcH8 was tested for binding to IQGAP1. TAP-Herc5 was used as 
a positive control. A break down product of Herc5 is indicated by (*).  
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To define the domains of Herc5 that bind IQGAP1, a series of Herc5 truncations 
were expressed as TAP-fusions and purified from 293T cells (Fig 5.7). Residues 1-377 of 
Herc5 containing the RCC1-like repeats, were sufficient to bind IQGAP1 at a level 
comparable to full length Herc5 (Fig 5.8). A protein spanning residues 381-1024, that 
includes the putative substrate binding box (SBB) and the HECT domain, was unable to 
bind IQGAP1, as was the HECT domain alone (Fig 5.8). Therefore, the determinants of 
Herc5 required for binding IQGAP1 lie within the first 377 amino acids of the protein. 
This region of the protein consists of four tandem RCC repeats from residues 156-377, 
with a fifth RCC repeat with low match score (Pfam) between residues 129 and 153. No 













Figure 5.7 A schematic showing the truncation mutants of Herc5 tested for 
binding to IQAP1. The RLD, SBB and HECT domains are shown in green, 













Figure 5.8 The N-terminal 377 amino acids of Herc5 are sufficient for binding 
IQGAP1. Wild type Herc5 and various mutants were expressed a  TAP fusions 
in 293T cells. The TAP proteins were purified and immobilized on IgG-
sepharose beads and incubated with purified IQGAP1for 2hrs at 4 oC. The 
beads were subsequently washed, resuspended in 1X loading buffer and loaded 
on an SDS-PAGE. The gel was transferred to a nitrocellulose membrane and 
bound IQGAP1 was detected by western blotting (upper anel). Lane 1 shows 
the input, which is 1/5 the amount used in the assays. Lane 2 indicates the 
amount of IQGAP1 bound to IgG sepharose beads only and is considered the 
background. The lower panel shows the TAP-tagged proteins. A break down 























































































































































To map the IQGAP1 domains essential for Herc5 binding, an in vivo binding 
assay was used. TAP-tagged truncation mutants of IQGAP1 (A-C, Fig 5.9) were co-
expressed with Myc-tagged Herc5 in 293T cells. Extracts were bound to IgG sepharose 
beads and western blots were probed with anti-Myc antibody to detect bound Herc5. 
Figure 5.10 shows that a significant amount of Myc-Herc5 bound to IgG-sepharose beads 
in the absence of TAP-IQGAP1 protein, creating a high background for the binding 
assay. In spite of this, we could detect an increased amount of Myc-Herc5 bound to full-
length TAP-IQGAP1 (Fig 5.10, lane 2 versus 3). The C-terminal 657 residues of 
IQGAP1 were sufficient to bind Herc5 (IQGAP1-A). This part of the protein contains 
two domains, the Ras-GAP related domain (GRD) and the Ras GAP C-terminus (RGCT), 
which have been previously shown to bind Rac1, Cdc42, β-catenin and E-cadherin (137). 
However, a larger construct spanning residues 525-1657 (IQGAP1-C), bound Myc Herc5 
better than the one with the last 657 amino acids only. This indicates that there might be 
more than one determinant within IQGAP1 for binding Herc5. IQGAP1-C includes a 
WW domain and four IQ repeats besides the GRD and RGCT. WW domains are protein-
protein interaction motifs with a known preference for PPXY sequences. An inspection 
of the Herc5 sequence did not reveal any PPXY motifs. The construct spanning the N-
terminal 525 residues of the protein (IQGAP1-B) didnot show any significant binding to 
Myc-Herc5. The results indicate that the C-terminal 657 amino acids of IQGAP1 mediate 
Herc5 interactions. In the future, both the domains comprising the C-terminus, that is, the 
GRD and RGCT, will have to be expressed separately to determine whether one of these 
















Figure 5.9 A schematic of IQGAP1 mutants used to test for binding to Herc5. 
Figure 5.10 The C-terminal 657 residues of IQGAP1 are sufficient to bind Herc5 
in vivo. TAP-tagged IQGAP1 truncation mutants (A-C) were co-expressed with 
Myc-tagged Herc5 in 293T cells. Extracts were bound to IgG sepharose beads for 
2 hrs at 4 oC after which the beads were washed, and loaded on an SDS-PAGE. 
The gel was transferred to a nitrocellulose membrane and the blots were probed 
with anti-Myc antibody to detect bound Herc5. Lane 1 shows the input and lane 2 



























IQGAP1 affects activity of wild type Herc5 but not ∆RCC or ∆SBB mutants 
As shown previously, Herc5 is able to conjugate ISG15 to itself, similar to other 
ubiquitin E3s that have the ability to ligate ubiquitin to themselves. This self-conjugation 
activity is absent in the C994A mutant of Herc5, which is a catalytically inactive enzyme. 
If IQGAP1 was functioning simply as an adaptor protein to recruit substrates to Herc5, 
knocking down IQGAP1 would not be expected to affect its ability to catalyze auto-
conjugation. To determine whether IQGAP1 was required for the auto-conjugation 
function of Herc5, HeLa cells were treated with siRNAs against IQGAP1, and 
subsequently transfected with Ube1L, UbcH8, ISG15 and TAP-Herc5 expressing DNA. 
Fig 5.11 shows that there was less ISG15-modified Hrc5 in cells where IQGAP1 was 
knocked down, whereas the control siRNA had no effect. This suggests that IQGAP1 is 










Figure 5.11 IQGAP1 is required 
for Herc5 auto-conjugation. HeLa 
cells were mock transfected (lane2) 
or transfected with IQA (lane 3) or 
a control siRNA (lane 4). After 24 
hrs, they were transfected with 
plasmids expressing Ube1L, 
UbcH8, ISG15 and TAP-Herc5. 
Cells were harvested 48 hrs post-
transfection and extracts were 
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I also determined whether the activity of other Herc5 mutants is similarly affected 
by IQGAP1. As shown in Chapter 4, the ∆RCC1 and ∆SBB mutants retain the ability to 
auto-conjugate ISG15 and both the mutants were able to auto-conjugate ISG15 better 
than wild type Herc5. As with the wild type protein, anti-TAP western blots were used to 
detect auto-conjugation of Herc5 mutants. Fig. 5.12 shows some wild type protein 
remained unmodified whereas under similar conditions, both ∆RCC1 and ∆SBB mutants 
were completely conjugated and appeared as a smear of high molecular weight 
conjugates at the top of the gel. Unlike wild type H rc5, the auto-conjugation activity of 
these mutants remained unaltered in the absence of IQGAP1 (Fig. 5.12). These results 
suggest a model in which the wild type protein is in an inactive conformation and 
requires IQGAP1 for its activity. In contrast, the ∆RCC1 and ∆SBB mutants are 
constitutively active and hence are unaffected by the presence or absence of IQGAP1. 
The fact that both the mutants show increased activity suggests that the N-terminus of the 
protein might be interacting with the SBB to keep Herc5 in a closed, catalytically inactive 
conformation and deleting either of these domains relieves the inhibition. I speculate that 















5.12 IQGAP1 is not required for auto-conjugation of ∆RCC and ∆SBB mutants. 
HeLa cells were mock transfected or transfected with IQA siRNA or a control 
siRNA, as indicated. After 24 hrs, they were transfected with plasmids 
expressing Ube1L, UbcH8 and ISG15 along with wild type TAP-Herc5 (left 
panel), ∆SBB mutant (middle panel) or ∆RCC mutant (right panel). Cells were 
harvested 48 hrs post-transfection and extracts were immunoblotted with anti-




























































Ube1L and UbcH8 are the primary E1 and E2 enzymes for ISG15 respectively. 
My previous work showed that Herc5 is the major ligase for this Ubl. Here we identify 
another factor, IQGAP1, as being required for Herc5-dependent ISG15 conjugation. 
IQGAP1 was identified in a proteomics study as one f many proteins modified 
by ISG15. My results confirmed this observation andfurther showed that the 
modification of IQGAP1 is Herc5-dependent, as is most, if not all, ISG15 conjugation. It 
is typical for enzymes of a Ubl pathway to be modifie  by their respective Ubls (21, 145), 
and IQGAP1 might be similarly conjugated simply based on its close association with 
Herc5. It is not known whether IQGAP1 modification is, in turn, required for its activity 
in the ISG15 conjugaiton pathway. Future experiments may identify the site(s) of ISG15 
modification on IQGAP1 in order to determine whether modification at those sites is 
required for its function in the ISG15 system.  
As mentioned in Chapter 3, an in vitro ISG15 conjugation assay was reconstituted 
using purified Ube1L, UbcH8, ISG15 and Herc5. Herc5 purified from insect cells did not 
form a thio-ester bond with ISG15, nor did it modify known, purified substrates. 
However, when transfected 293T cells were used as a source of Herc5, conjugation was 
detected. This might now be explained in light of IQGAP1. Here it has been shown that 
knocking down IQGAP1 inhibits the activity of Herc5, and hence the Herc5 purified 
from insect cells (which do not have an IQGAP1 homolog) would not be active without 
IQGAP1 in the reaction mix. However, in spite of including purified IQGAP1 in the in 
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vitro reaction assay I did not detect a Herc5~ISG15 thio-ester bond. This could mean that 
yet other factors required for ISG15 conjugation are missing. 
ISG15 was shown to act as an antiviral molecule in mice infected with influenza 
virus and Sindbis virus and conjugation of ISG15 to substrates was important for this 
function (105). It might be predicted that a protein which boosts ISG15 conjugation 
might also have an anti-viral role. My data shows that IQGAP1 is needed for activating 
Herc5, which in turn is necessary for conjugating ISG15 to substrates and hence, 
IQGAP1 could be a potential anti-viral protein. So far, there have been no reports that 
tested this possibility. Mice lacking IQGAP1 have no obvious phenotypes other than a 
propensity for gastric hyperplasia (108), but no experiments were reported that would 
have specifically determined the response of these mic to viral infections. IQGAP1-/- 
mouse embryonic fibroblasts have been recently described (153), and these might be 
useful for  testing whether IQGAP1 is involved in antiviral responses.  
Binding studies show that IQGAP1 interacts with Herc6, but the binding is less as 
compared to that seen with Herc5. This is consistent with results showing Herc5 to be the 
major E3 for ISG15, with Herc6 playing a minor role. Herc4, which does not play any 
role in ISG15 conjugation, did not interact with IQGAP1. It is tempting to speculate that 
the interaction of Herc5 with IQGAP1 might be responsible for recruiting substrates to 
Herc5 to be ISG15 conjugated. IQGAP1 is a 189 kDa protein with multiple domains and 
it is plausible that different subsets of target proteins bind different domains. However, in 
preliminary experiments to pull down substrates from IFN-β-treated cell extract on TAP-
IQGAP1-IgG-sepharose, no ISG15 conjugates were detected (data not shown). 
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My results suggest that IQGAP1 interacts with Herc5 and activates it. There have 
been other reports of IQGAP1 modulating the activities of its binding partners. For 
example, IQGAP1 inhibits the β-catenin-E-cadherin complex, leading to decreased cell-
cell adhesion (103), whereas it enhances the co-transc iptional activation function of β-
catenin in a calmodulin-dependent manner (11). IQGAP1 also alters the EGF-mediated 
activation of B-Raf, MEK and ERK2  proteins (153, 158, 159). Further, a recent report 
claimed that IQGAP1 decreased the amount of activated Rap1, which is in contrast to its 
effect on other small GTPases like Cdc42 and Rac1 (76). No enzymatic activity has so far 
been detected for IQGAP1 and in all the above examples it modulates the activity of its 
interacting partners by either displacing other proteins from a complex or recruiting 
activators/inhibitors. It is possible that in the case of Herc5 too, IQGAP1 recruits a 
protein which in turn activates the ligase. 
The results so far, indicate a model in which Herc5 is in a closed conformation 
and requires IQGAP1 to activate it (Fig 5.13). I speculate that the N-terminus of Herc5 
might bind to the SBB to keep the protein in a closed inactive state. When IQGAP1 binds 
the RCC1-like repeats, it disrupts the intramolecular interaction between the N-terminus 
and the SBB and the protein is activated. Additionally, IQGAP1 might also function by 
recruiting substrates to Herc5 by virtue of its modular structure. This would explain why 
the ∆RCC1 mutant, which does not interact with IQGAP1, could conjugate ISG15 to 
itself, but not to other substrates. The HECT E3 Smurf2 is similarly regulated by an auto-
inhibitory mechanism (140). The intramolecular interaction between the C2 and HECT 
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domains inhibits Smurf2 activity. The inhibition is counteracted by an adaptor protein 
Smad7, which binds the HECT domain and activates th ligase activity. Future 
experiments in the lab will be aimed towards testing his model. I will investigate 
whether the N-terminus of Herc5 has an affinity for its C-terminus, as predicted by this 
model. The model also predicts that adding increasing amounts of the Herc5 N-terminal 
fragments should relieve the auto-inhibitory conformation by competing for binding to 
the SBB, and in that case, the protein should no loger be dependent on IQGAP1 for 
activation. Also, efforts will be made to reconstitute an in vitro assay, since biochemisty 
will greatly enhance our understanding of this system. Further, I cannot completely rule 
out the possibility that IQGAP1 might interact with other enzymes of the ISG15 pathway, 
although, so far I have no evidence that supports it. As mentioned in the introduction, 
IQGAP1 co-ordinates multi-protein complexes that are important for cell motility, cell-
cell adhesion, and MAP kinase signal transduction. It might similarly function to increase 
the local concentrations of ISG15 enzymes and prevent ubiquitin enzymes like E6AP 












Figure 5.13 A model for the role of IQGAP1 in Herc5-mediated ISG15 conjugation. The 
N-terminus of Herc5 might bind to the SBB to keep the protein in a closed inactive state. 
When IQGAP1 binds the RCC1-like repeats, it disrupts the intramolecular interaction 
between the N-terminus and the SBB and the protein is activated. Additionally, IQGAP1 
might also function by recruiting substrates to Herc5 by virtue of its modular structure. 
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CHAPTER 6: FUTURE DIRECTIONS  
My work has shown that Herc5 is the major ligase for ISG15, an antiviral 
ubiquitin-like protein, and that IQGAP1 interacts with Herc5 and is required for Herc5 
activity in vivo. I have identified two novel factors that play a role in ISG15 conjugation, 
and these findings add significantly to our knowledg  of the ISG15 pathway. 
One of the most important aspects of my work is that it will be useful for 
reconstituting an in vitro system for ISG15 conjugation. Previously, Ube1L and UbcH8 
had been identified as the E1 and E2 enzymes, respectively, for ISG15. Also, a 
proteomics approach had identified more than 150 proteins as substrates of ISG15 
conjugation. With the discovery of the E3, and its as ociated protein IQGAP1, we may 
have identified all the factors required for reconstitution of ISG15 conjugation. An in 
vitro assay will be an invaluable tool that will help us address many questions. It will be 
crucial for determining the biochemical consequences of ISG15 modification of target 
proteins. Modification of targets by other Ubls (e.g., Sumo) causes changes in 
localization, activity, or protein-protein interactions. ISG15 may be performing similar 
roles, although so far there is little evidence for any of the above. ISG15 modification of 
Ubc13 was reported to abrogate its ability to form a thioester bond with ubiquitin because 
the ISG15 modification site was just 5 residues from the active site cysteine and stearic 
hindrance prevented the interaction with ubiquitin (170, 198). Although the protein 
phosphatase 2Cbeta (PP2Cbeta), which is involved in NFκB pathway, was shown to have 
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a decreased activity when it was conjugated to ISG15, the effect was very subtle (169). 
4EHP, an mRNA cap-binding protein and a suppressor of translation, was reported to be 
modified by ISG15 via the RING-type ligase HHARI and this increased its cap-binding 
affinity (142) . However, the data suggests that the increase in cap-binding affinity was 
not significant. None of these reports gave a convincing demonstration of the effect of 
ISG15 conjugation. An in vitro conjugation system for ISG15 would be useful for 
determining the biochemical effects of ISG15 on specific activities of target proteins. We 
could isolate the modified product and look for changes in its ability to interact with 
known binding partners. Further, such a system would be essential to understand the 
biochemistry involved in Herc5-dependent conjugation. It would allow us to isolate any 
further factors that might be required for ISG15 conjugation and/or recruitment of 
specific target proteins to the Herc5/IQGAP1 complex. Mutants of Ube1L, UbcH8, 
Herc5 and ISG15 could be tested for activity without the complications involved in i  
vivo assays. The effect of other factors such as IQGAP1 would also be more clearly 
understood using biochemistry. The in vitro system described in Chapter 3 is a good 
starting point for establishing assays for Herc5 activity. Although those assays are crude 
and use whole cell extract, they are the first direct evidence of Herc5 activity. In the 
future, that assay will have to be refined and used with purified Herc5 and IQGAP1.  
An important aspect that needs to be studied is the identification of sites of ISG15 
modification on substrates. Although we now have a list of more than 150 substrates 
modified by ISG15, the sites of ISG15 attachment to only Ubc13, EFP and PP2Cbeta are 
known (169, 198, 199). As more data about the conjugation sites accumulates, it might 
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yield a consensus structure/motif that is recognized by Herc5. In addition, we will be able 
to mutate the sites and transfect the mutant proteins into cells to check for a change in 
localization and/or function. This is especially important for known antiviral proteins, 
including p56 and nine other antiviral proteins that were identified as substrates for 
ISG15 conjugation. In the case of IQGAP1, identification of its site of modification will 
allow us to determine whether ISG15 conjugation is required for its Herc5-related 
function. It will also be important to ascertain the fidelity of any in vitro conjugation 
system and one of the ways to do that would be to check whether the same sites are being 
modified on a substrate in vitro, as they are in vivo. Further, identifying sites of ISG15 
modification will allow us to determine whether poly-ISG15 chains are formed on target 
proteins. Most substrates modified by ISG15 show a single conjugate. However, some 
like p56 and moesin, exhibit multiple conjugates. Recently, SUMO was shown to form 
short chains (99) and it is possible that ISG15 forms chains, given that the K-48 residue 
on ubiquitin is conserved in the C-terminal domain of ISG15 (K-129). 
A significant aspect of my work is the discovery that a HECT E3 was shown to 
function with a Ubl other than ubiquitin. While the RING E3s function with both 
ubiquitin and some Ubls (128, 186), HECT domain proteins were known to act as E3s for 
ubiquitin only. This new finding further broadens the spectrum of biological processes 
that HECT proteins participate in. My preliminary results with the active site mutant 
(C994A) and the ∆F mutant suggest that the mechanism of ubiquitin and ISG15 
conjugation are identical. So far, we know that HECT domains have the inherent 
structure to function with ISG15 and this was shown by in vitro experiments with E6AP 
 
133 
and Rsp5 (196).What we do not know is whether Herc5 can function with ubiquitin or 
whether it is exclusively devoted to ISG15. It is es ntial to make active Herc5 in vitro, 
so that we can test whether it functions with ubiquit n. If Herc5 does not form a thioester 
with ubiquitin in vitro, then we can investigate the determinants within Herc5 that 
prevent it from functioning with ubiquitin.  
Another interesting result of my work was that Herc6 was shown to function with 
ISG15, albeit not as efficiently as Herc5. It was not clear why the chimera Herc5/6, 
which had the Herc6 HECT domain and the rest of the protein from Herc5, did not 
support conjugation of ISG15 to substrates. There might be unique features of the N-lobe 
or C-lobe of Herc5 and maybe making chimeras in this region of the protein might be 
useful. As discussed in Chapter 4, I suggest that since Herc5 is absent in rodents, Herc6 
might be the major ligase for ISG15 in these organisms. This possibility needs to be 
tested. Herc6 can be knocked down in interferon-treated mouse cells to determine 
whether it has an effect on substrate conjugation. If Herc6 is important for ISG15 
conjugation in mice, knockout mice that lack the gene for Herc6 can be created. This 
would provide an animal model to test the role of ISG15 ligases and might provide us 
with some new insights into non-ISG15-related roles for Herc6 and Herc5. Such a mouse 
model would resolve the confusion in the ISG15 field about the role of the other ligase 
TRIM25/EFP. Although I did not see an overall effect on ISG15 conjugates when 
TRIM25/EfP was knocked down, it has been postulated to function as an ISG15 ligase 
for the negative cell cycle regulator 14-3-3σ (200). The finding that it conjugates ISG15 
to the same substrate (14-3-3σ) which it ubiquitinates, could be because in interferon-
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treated cells, the high levels of UbcH8, ISG15 and Efp/TRIM25, might force the ligase to 
react with ISG15. Also, the levels of Efp auto-conjugated to ISG15, were much lower 
than the levels of ubiquitin-conjugated Efp (134), suggesting that it functions more 
efficiently with ubiquitin. Finally, a recent report by Gack et al showed that Efp/TRIM25 
was essential for RIG-I mediated anti-viral activity (35). Efp/TRIM25 mediates robust 
ubiquitination of the caspase recruitment domains (CARDS) of RIG-I, which enhances 
RIG-I downstream signaling. This role of Efp/TRIM25 might explain why a ubiquitin 
ligase is upregulated in the presence of interferons. A Herc6 knockout mouse would be 
very useful to clarify whether there are any redundant ISG15 ligases. If no ISG15 
conjugates are detected in such a mouse, it would conclusively tell us that Herc6 (and 
Herc5 in humans) is the only ligase for ISG15. 
Besides Herc5, I also identified a non-interferon induced protein, IQGAP1, which 
is essential for ISG15 conjugation. My results suggest that IQGAP1 might be functioning 
in the ISG15 pathway by binding the N-terminus of Herc5 and facilitating its activation. 
Further experiments will need to be done to test the model. For example, we need to 
determine whether the N-terminus of Herc5 interacts wi h the SBB. Also, given the 
modular nature of IQGAP1, it might function as an adaptor to recruit substrates or it 
might act as a scaffold to recruit the enzymes of the ISG15 pathway. The IQGAP1-/- cell 
line (153) is a useful tool and can be used in future experiments to test various mutants of 
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